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ABSTRACT 
The lungs are constantly exposed to microorganisms and environmental irritants. Pulmonary 
inflammation is the result of an immune process to protect the body, and may sometimes eventually result 
in disease. T cells including various subsets are of major importance for orchestrating the protection of the 
lung as well as for inflammatory reactions. Activated pulmonary T cells not only have the potential to 
affect the lungs themselves, but they could contribute to immune responses in other organs as well. The 
overall aim of the study presented in this thesis was to investigate the potential effect of T cell immune 
responses for chronic lung inflammation from two different aspects. We thus first  investigated antigen-
specific T cell responses in patients with pulmonary sarcoidosis, and in the second part determined how 
smoking affected lung T-cell immunity, with regard to the influence of smoking in the development of 
autoimmunity. 
Sarcoidosis is a granulomatous systemic inflammatory disorder which commonly affects the lungs. T 
cells and particularly activated CD4+ T cells are considered to be involved in the pathogenesis of the 
disease. A subgroup of sarcoidosis patients known as Löfgren’s syndrome differs strikingly from other 
patients by particular clinical symptoms. Spontaneous recovery within two years is particularly common in 
Löfgren´s syndrome patients who are HLA-DRB1*0301positive, and these patients virtually always have 
accumulations of T cells expressing a particular T cell receptor (TCR) V gene segment, termed AV2S3, in 
the lungs. The aetiology of sarcoidosis is still not known. However, recently a specific mycobacterial 
protein, M. tuberculosis catalase-peroxidase (mKatG) was identified in sarcoidosis tissues.  
BAL CD4+ T cells from HLA-DRB1*0301positive Löfgren’s syndrome responded to mKatG with a 
more pronounced multifunctional cytokine profile, i.e. with simultaneous production of IFNγ and TNF 
compared to non-Löfgren’s syndrome patients. Non-Löfgren’s syndrome patients instead responded with a 
higher proportion of cells producing single cytokines, i.e. production of IFNγ alone. Moreover, AV2S3+ 
CD4+ T cells from both BAL and blood had a higher IFNγ production in response to mKatG compared to 
AV2S3- CD4+ T cells, while the opposite was found for BAL AV2S3+ CD4+ cells in response to PPD. 
Furthermore, BAL T cells from Löfgren´s syndrome patients had compared to T cells of non Löfgren´s 
syndrome higher frequencies of IL-17-producing cells in response to mKatG. Löfgren´s syndrome HLA-
DRB1*03 positive patients clearly had higher levels of IL-17 in BAL fluid compared to healthy controls 
and to patients without Löfgren’s syndrome. Our results indicate that the quality of the T cell response in 
sarcoidosis patients may play a key role in disease presentation and clinical outcome. These findings imply 
that the presence of multifunctional BAL CD4+ T cells, higher activities of TCR AV2S3+ CD4+ T cells, 
and more pronounced IL-17 production in particular subgroups of sarcoidosis patients are involved in 
antigen elimination at the site of inflammation and may play a role in spontaneous recovery, typical for 
patients with Löfgren´s syndrome (in particular DRB1*03 positive). 
Cigarette smoking is a well-known risk factor for several inflammatory and autoimmune disorders. 
The risk of developing multiple sclerosis (MS) is strongly increased by smoking in people with genetic 
susceptibility. Smoking is associated with both release and inhibition of pro-inflammatory and anti-
inflammatory mediators that influence different T cell subsets. Our results indicate that cigarette smoke 
induces a decline in lung Th17 cells and alters the phenotype of T regulatory cells by decreasing the 
proportion of IL-10 producing Foxp3+ CD4+ cells and increasing the fraction of lung Foxp3+ Helios 
negative T cells. Thus, an imbalance between Th17/Tregs may be caused by cigarette smoking, which 
could result in an increased risk for infection and may also have consequences for autoimmune processes 
postulated to be initiated in the lung. Furthermore we studied the effect of smoking and conventional 
treatment in the lungs and blood of MS patients compared to healthy individuals. We found that the 
frequency of Foxp3+Helios+ regulatory T cells, important in the context of autoimmunity, was reduced 
in BAL of MS patients. However, the frequencies of both this subset of Tregs and of total Foxp3+ CD4+ 
BAL Treg cells was increased after treatment particularly in IFNβ treated MS patients. If the lungs are 
involved in initiation and propagation of inflammatory processes in MS, the observed effects in IFNβ-
treated patients may be involved in disease amelioration in MS patients following such treatment.  
  
LIST OF SCIENTIFIC PAPERS 
 
I. Maria Wikén, Mahyar Ostadkarampour, Anders Eklund, Matthew Willett, Edward 
Chen, David Moller, Johan Grunewald, Jan Wahlström; Antigen-specific 
multifunctional T-cells in sarcoidosis patients with Löfgren’s syndrome; he 
European Respiratory Journal, 2012 Jul;40(1):110-21 
 
 
II. Mahyar Ostadkarampour, Anders Eklund, David Moller, Pernilla Glader, Caroline 
Olgart Höglund, Anders Lindén, Johan Grunewald, Jan Wahlström; Higher levels 
of IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients 
with Löfgren’s syndrome; Clin Exp Immunol. 2014 Nov;178(2):342-52. doi: 
10.1111/cei.12403. 
 
 
III. Mahyar Ostadkarampour, Malin Müller, Johan Öckinger, Susanna Kullberg, 
Anders Eklund, Johan Grunewald, Jan Wahlström; Cigarette smoke induces 
distinctive Tregs and a Treg/Th17 imbalance in the lungs (Submitted) 
 
 
IV. Mahyar Ostadkarampour, Susanna Kullberg, Johan Öckinger, Anders Eklund, 
Fredrik Piehl, Tomas Olsson, Johan Grunewald, Jan Wahlström; Characteristics of 
lung T cell subsets in multiple sclerosis patients with respect to smoking and beta-
interferon treatment (Manuscript) 
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 General introduction .................................................................................................. 1 
1.2 The immune system .................................................................................................. 1 
1.3 Innate immunity ........................................................................................................ 1 
           Innate immunity components ......................................................... 1 
1.4 Adaptive immunity .................................................................................................... 2 
     1.4.1 B cells ...................................................................................................... 2 
     1.4.2 T cells ....................................................................................................... 3 
 1.4.2.1 CD4+ T cells ................................................................................. 3 
          Th1 subset ......................................................................................... 3 
          Th2 subset ......................................................................................... 4 
          Th17 subset....................................................................................... 4 
           Regulatory T cell (Treg) subset ...................................................... 4 
           Other subsets of T cells ................................................................... 5 
           T cell plasticity ................................................................................ 7 
 1.4.2.2 CD8+ T cells ................................................................................. 7 
1.5 Antigen presentation and human leukocyte antigen (HLA) .................................... 7 
1.6 The T cell receptor .................................................................................................... 8 
1.7 T cell activation ......................................................................................................... 9 
1.8 The respiratory system ............................................................................................ 10 
     1.8.1 Immunology of the lungs ...................................................................... 11 
     1.8.2 Interstitial lung diseases ........................................................................ 12 
 1.8.2.1 Sarcoidosis .................................................................................. 13 
           Clinical aspects .............................................................................. 13 
           Pathogenesis .................................................................................. 13 
           mKatG ........................................................................................... 14 
           Immunopathogenesis .................................................................... 14 
           Treatment ....................................................................................... 15 
           Löfgren’s syndrome ...................................................................... 15 
     1.8.3 Smoking induced-inflammation ........................................................... 16 
           Smoking-induced autoimmunity .................................................. 17 
           Smoking-induced multiple sclerosis ............................................. 17 
2 Aims ............................................................................................................................... 19 
3 Comments on methodology .......................................................................................... 20 
3.1 Study subjects .......................................................................................................... 20 
3.2 Sampling .................................................................................................................. 20 
           Bronchoalveolar lavage ................................................................ 20 
           Peripheral blood mononuclear cells ............................................. 21 
3.3 Methodology ........................................................................................................... 21 
           T cell stimulation ........................................................................... 21 
           Flow cytometry ............................................................................. 22 
  
           Elispot ............................................................................................ 22 
           Quantitative immune PCR ............................................................ 23 
           Immunohistochemistry ................................................................. 23 
           Statistical analysis ......................................................................... 24 
4 Results and discussion ................................................................................................... 25 
4.1 Antigen-specific Th1 responses in sarcoidosis (Paper I) ....................................... 25 
4.2 IL-17 and antigen-specific IL-17-responses in sarcoidosis (Paper II) .................. 29 
4.3 Characteristics of effector and regulatory T cell subsets in the lungs of 
smoking and non-smoking healthy individuals (Paper III) ................................ 33 
4.4 Characteristics of lung T cell subsets in multiple sclerosis patients       
(Paper IV) ............................................................................................................ 37 
5 Conclusions ................................................................................................................... 40 
6 Concluding remarks and perspectives .......................................................................... 41 
7 Acknowledgements ....................................................................................................... 43 
8 References ..................................................................................................................... 46 
 
  
  
LIST OF ABBREVIATIONS 
ACPA Anti citrullinated protein antibody 
AHR Aryl hydrocarbon receptor 
AM Alveolar macrophage 
APC Antigen presenting cell 
AV2S3 Variable gene segment 2.3 of the T cell receptor α chain 
BAL Bronchoalveolar lavage 
BCR B cell receptor 
BFA Brefeldin A 
BHL Bilateral hilar lymphadenopathy 
CBD Chronic beryllium disease 
CCR Chemokine receptor 
CD Cluster of differentiation 
CDR Complementarity determining region 
COPD Chronic obstructive pulmonary disease 
CTLA-4 Cytotoxic T lymphocyte-associated antigen 4 
DAMP Damage Associated Molecular Pattern 
DC Dendritic cell 
DLCO Diffusing capacity of the lung for carbon monoxide 
EAE Experimental autoimmune encephalomyelitis 
EAU Experimental autoimmune uveitis 
FACS Fluorescence-activated cell sorter 
FEV1 Forced expiratory volume in 1 second 
Foxp3 Forkhead box protein 3 
FVC Forced vital capacity 
GITR Glucocorticoid-induced TNF receptor family 
HLA Human leukocyte antigen 
IBD Inflammatory bowel disease 
ICAM-1 Intercellular adhesion molecule-1 
IDO Indoleamine 2,3-dioxygenase 
IFNγ Interferon-γ 
Ig Immunoglobulin 
IL Interleukin 
ILD Interstitial lung disease 
iNKT invariant natural killer T cell 
IPF Idiopathic pulmonary fibrosis 
  
iTreg Induced regulatory T cell 
LPS Lipopolysaccharide 
MAIT Mucosa-associated invariant T cells 
MFI Median (or mean) fluorescence intensity 
MHC Major histocompatibility complex 
mKatG Mycobacterial catalase-peroxidase 
MS Multiple sclerosis 
NLR NOD like receptor (nucleotide-binding oligomerization domain) 
NK Natural killer 
PAMP Pathogen associated molecular pattern 
PBL Peripheral blood lymphocytes 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PHA Phytohaemagglutinin 
PPD Purified protein derivative 
PRR Pattern recognition receptor 
pTreg Peripheral regulatory T cell 
qIPCR quantitative immuno-PCR 
RA Rheumatoid Arthritis 
RNS Reactive Nitrogen Species 
ROS Reactive Oxygen Species 
SEA Staphylococcus enterotoxin A 
SEB Staphylococcus enterotoxin B 
STAT Signal Transducer and Activator of Transcription 
TCR T cell receptor 
Tfh Follicular helper T cell 
TGFβ Transforming growth factor-β 
tTreg Thymus-derived regulatory T cell 
Th cell T helper cell 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
  
  
  1 
1 INTRODUCTION 
1.1 General introduction 
Inflammation is a biological process with accumulation of leukocytes and dissemination of 
fluid and proteins in the inflamed tissue in response to infection, irritation, injury or physical 
stress. Acute inflammation is an important immune response to protect against pathogens. 
The inflammation usually clears after pathogen elimination, while if e.g. autoimmunity is 
induced or a pathogen persists there may be chronic inflammation which may lead to tissue 
destruction or fibrosis. Inflammation is an essential component of many lung disorders. T 
helper lymphocytes have a pivotal role in orchestrating the inflammatory reaction following 
triggering by specific antigens. In this thesis my aim is to better understand the role of T-cell 
immunity in pulmonary inflammation by focusing on the inflammatory interstitial lung 
disease sarcoidosis and by studying the effect of smoking on lung T cells with regard to the 
influence of smoking in developing autoimmune disease. 
1.2 The immune system 
The immune system protects the host from a variety of pathogens including bacteria, viruses 
and parasites and is also activated by stressed cells like malignant cells or cells with damaged 
DNA. Innate immunity provides the first line and initial immune responses against 
pathogens, while adaptive immunity consists of highly specialized immune responses against 
pathogen specific antigens. 
1.3 Innate immunity 
Innate immunity is a complex of early response mechanisms that provide the first-line 
defense to control and eliminate pathogens. The innate cells eradicate pathogens by rapid 
phagocytosis or release of killing substances; moreover they induce delayed cellular 
responses by activating signaling pathways that promote recruitment of more effector cells. 
Innate immunity components 
The first line of defense by the innate immunity system consists of physical (epithelial) or 
chemical (specialized substances) barriers. There are several substances (mostly proteins) 
which can protect the body from pathogens. Lysozyme, surfactants and defensins are 
examples of substances which are found in mucosal epithelia and the respiratory tract and 
that protect the body from invading pathogens by different mechanisms. If pathogens evade 
these defenses, then they encounter the cellular responses of innate immunity. 
The cellular components of innate immunity react against the invading pathogens via 
receptors named pattern recognition receptors (PRR). PRR can recognize special structures 
on pathogens or stressed cells, but not normal host cells. These special structures which are 
common to many different pathogens or damaged cells are named pathogen associated 
molecular patterns (PAMP) or damage associated molecular patterns (DAMP).  
PRRs are receptors which are expressed on the cell surface or intracellularly by a variety of 
cells and they contribute in activation of innate immunity. Toll like receptors (TLR), NOD 
like receptors (NLR) and Retinoic acid-inducible gene-I-like receptors (RLR) are examples 
of PRRs that can recognize many types of pathogen molecules. Examples of such lignds are 
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lipopolysaccharide (LPS) or peptidoglycan (presented by gram negative and gram positive 
bacteria respectively), double stranded RNA and unmethylated CpG DNA (1). 
Phagocytic cells including neutrophils and macrophages engulf pathogens which are 
subsequently destroyed inside the phagosome. Reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are two well-studied digestive mechanisms which have the ability to 
destroy phagosome contents. NADPH oxidase and inducible nitric oxide synthase (iNOS) are 
two important enzymes that generate bactericidal ROS and NO respectively. These enzymes 
are activated when pathogens bind to PRRs. Phagosome fusion with lysosomes containing 
proteolytic protease enzymes is another important mechanism which helps to destroy 
ingested pathogens (2). 
Natural Killer cells (NK cells) are a class of lymphoid cells which react against pathogens 
and abnormal cells. Lack of MHC class I, often induced by viral infection of a cell, is a signal 
for activation of these efficient killer cells to secrete cytotoxic granules. Moreover, NK cells 
by secretion of cytokines help to activate other immune cells (3). 
In addition, there are several unconventional lymphocyte subsets that are classified as parts of 
innate immunity. Cells like γδ T cells, invariant natural killer T (iNKT) cells, Mucosa-
associated invariant T cells (MAIT) and B-1 cells are lymphocytes that are activated in 
response to pathogens immediately when they recognize molecular patterns and have the 
capacity to immediately express effector functions (4). 
1.4 Adaptive immunity 
The second form of immunity that protects the host from invading pathogens is adaptive 
immunity. In contrast to innate immunity which responds to shared structures of pathogens in 
the early phase of infection, the function of adaptive immunity is defined by highly antigen 
specific responses against pathogens. Adaptive immunity responses develop later in the 
secondary phase to recognize and eliminate the pathogens more specifically and efficiently. 
The receptors in innate immunity are encoded by the germline DNA pattern, while in order to 
make an antigen specific response in adaptive immunity, receptors are encoded by gene 
segments that undergo somatic recombination to generate an enormous diversity of receptors. 
Immunologic memory is one important feature of adaptive immunity that allows more 
effective and rapid responses to occur during the second exposure to the antigens that the 
immune cells encountered before. The adaptive consists of B and T lymphocytes. 
1.4.1 B cells 
B cells are lymphocytes that mature in the bone marrow. Antibody production is the most 
prominent feature of B cells. B cells express immunoglobulin on their cell surface as the B 
cell receptor (BCR). Once B cells with cell surface immunoglobulin bind to specific matched 
antigens, they can internalize the antigen via endocytosis. B cells start to process internalized 
proteins into peptides and consequently they present antigenic peptides on their surface by 
MHC class II molecules to CD4+ T cells. If the T cell via its TCR recognizes the presented 
antigen it can provide help for B cell maturation. This response of B cells to antigens is 
classified as a T dependent response. B cells can also recognize non protein antigens via 
immunoglobulin without T cell involvement, which is called a T independent response. 
Activated B cells can differentiate into plasma cells that secrete soluble BCRs in the form of 
different classes of antibody. Secreted antibodies can protect the host by different 
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mechanisms. Antibodies help to destroy or inactivate the pathogens by neutralization 
(binding to pathogens can inhibit them from infecting other cells), opsonization (binding to 
pathogens will facilitate the phagocytosis by phagocytes) and finally by complement 
activation (a complex of serum proteins that via a catalytic cascade form mediators that help 
to destroy pathogens or make them suitable for phagocytosis) (2). 
Somatic recombination of the variable regions in the immunoglobulin heavy chain (V, D and 
J segment) and light chain (V and J segment) generates the diversity in BCR and antibodies 
(5). B cells initially produce IgM and IgD, while following interaction of B cells with T cells, 
class switching will happen and IgG, IgE and IgA are induced in a T cell mediated manner. 
1.4.2 T cells 
T cells are lymphocytes which are responsible for the so-called cell mediated immunity and 
they develop in the bone marrow followed by maturation in the thymus. T lymphocytes are 
divided into two main classes that are different in phenotype and function. T cells which 
carry the CD4 molecule on their cell surface are named helper T cells and they are involved 
in activating B cells and phagocytes to destroy the pathogens. The second class of T cells is 
named cytotoxic T cells; they carry the CD8 molecule on their surface and kill their target 
cells. Despite differences between CD4 and CD8 T cells, they share common features. Naïve 
T cells can only recognize pathogen-derived peptides which are presented by antigen 
presenting cells (APC). Both CD4 and CD8 T cells have T cell receptors on their surface 
which are highly specific and recognize a unique antigen that is presented by special 
molecules on the surface of APCs. When naive T cells recognize appropriate antigen 
presented by APCs in lymphoid organs they will differentiate into effector cells which have 
the ability to react against pathogens and migrate to peripheral sites to eliminate pathogens. 
Generation of memory T cells following activation of T cells is one of the most important 
features of T cells (quite similar to B cells) leading to a faster and more effective response 
when the host encounters a secondary challenge with the same pathogen (6). 
1.4.2.1 CD4+ T cells 
CD4 T cells constitute a major subset of T cells that perform a pivotal role in the immune 
system. When naive CD4 T cells encounter their cognate antigen presented on APCs, they 
differentiate into effector and/or memory cells. CD4 T cells are named T helper cells because 
they have the ability to e.g. help B cells produce antibody. CD4 T cells help B cells to mount 
antibody responses, provide feedback to DCs via costimulatory molecules, prime the immune 
system by cytokine and chemokine secretion and maintain CD8 T cells responses (7). 
Moreover, CD4 T cells have direct effector activity, including performing cytotoxic functions 
(8) and mediating macrophage activation. Dysregulation of CD4 T cells is associated with 
many chronic diseases. CD4 T cells according to their phenotype and function are 
categorized into different subsets. Th1, Th2, Th17 and Regulatory T cells are the most well-
known T cell subsets (Figure 1). Polarizing cytokines, master gene regulators and cytokine 
signature are three major characteristics of each subset. 
Th1 subset 
Interleukin-12 (IL-12), IL-18 and Interferon γ (IFNγ) are key cytokines in Th1 polarization. 
IL-12 and IL-18 are cytokines that are produced by macrophages and DCs and which, 
together with IFNγ  produced by T cells, induce Signal Transducers and Activators of 
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Transcription 4 (STAT4)  (9) and up-regulate expression of T box expressed in T cells (T-
bet) as master regulator of Th1 cells. T-bet expression promotes Th1 commitment and 
induces Th1 cells to produce IFNγ (10). IFNγ, TNF and lymphotoxin α (LTα) are the most 
important Th1 cytokines (11). Th1 cells are involved in macrophage activation, antibody 
class switching (in B cells) and promotion of fully cytotoxic T cell activity. These functions 
by Th1 cells contribute to responses against viral and intracellular pathogens. 
Th2 subset 
IL-4 is the critical cytokine for polarization of Th2 cells and their differentiation is controlled 
by the master transcription factor GATA3. IL-4 acts by signaling via STAT6, which is the 
necessary signal transducer for Th2 differentiation (12, 13). IL-4, IL-5 and IL-13 are 
signature cytokines of Th2 cells (14). The main role of Th2 cells is clearance of extracellular 
parasitic infections. The secreted cytokines by Th2 cells induce eosinophil differentiation and 
promote production of IgE and IgG1 by B cells. Th2 cells also have important roles in 
mediating allergic reactions (15). 
Th17 subset 
The characterization of IL-17 producing T cells as a distinct T cell lineage was based on 
studies performed in the mouse model of MS,  experimental autoimmune encephalomyelitis 
(EAE) (16, 17). Differentiation of Th17 cells from naive CD4 T cells is controlled by RORc 
as master regulator (18). TGFβ (immunoregulatory cytokine) and IL-6 (proinflammatory 
cytokine) are two main cytokines which are required to induce IL-17 in naive T cells. Rorc 
expression is inhibited by a high concentration of TGFβ, while presence of TGFβ in 
combination with IL-6 causes induction of IL-17 expression (19, 20). IL-23 is another 
important cytokine in Th17 differentiation, and it has been considered as a cytokine needed in 
order to up-regulate IL-22 by Th17 cells (21) and necessary to attain full pathogenic potential 
through its maintenance and stabilization of the Th17 phenotype in autoimmunity (22). 
STAT3 is the main signal transducer in Th17 cells and not only causes increased expression 
of RORc molecule but it can directly bind to IL-17 and IL-21 promoters (23, 24). The main 
function of IL-17 in immunity against pathogens is due to its induction of pro-inflammatory 
cytokines and chemokines which orchestrate trafficking and activation of innate immune 
cells particularly neutrophils and macrophages (25). Many inflammatory or autoimmune 
diseases which were previously considered to be Th1-mediated disorders are now considered 
as Th-17-mediated diseases. 
IL-17 is actually a family of cytokines, which includes IL-17A (called IL-17), IL-17B, IL-
17C, IL-17D, IL-17E (called IL-25), and IL-17F (19). Among the IL-17 family members,  
IL-17A and IL-17F have the highest degree of homology and both IL-17A and IL-17F are 
produced by a variety of cell types and have pro-inflammatory properties (26). IL-17 family 
receptors also consist of five members (IL-17RA, RB, RC, RD and RE), all of which, like 
their ligands, share sequence homology (27). IL-17A and IL-17F signal through the IL-
17RA–IL-17RC heterodimeric receptor complex (28). 
Regulatory T cell (Treg) subset 
Regulatory T (Treg) cells is a distinct T cell subpopulation that is engaged in sustaining 
immunological self-tolerance and homeostasis (29, 30). The X-chromosome-encoded 
member of the Forkhead Transcription Factor box P3, named Foxp3 is a master regulator of 
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regulatory T cells (Treg) which controls differentiation and function of Tregs (31). Currently 
CD25 (IL-2 receptor subunit α) is the best surface marker to define Treg cells, although 
several markers have been described for Treg identification like CTLA-4 (cytotoxic T 
lymphocyte antigen-4), GITR (glucocorticoid-induced TNF receptor family), CD127
 low
 and 
IL-1 receptor although they are not completely Treg specific (32-35). 
The majority of Tregs develop in the thymus by high-avidity recognition of self-antigens and 
act to prevent damage caused by self-reactive T cells which evade the negative selection 
process (T cells with high affinity for self MHC/peptide); this group of T cells is named 
thymus-derived Tregs (tTreg) or natural Tregs (nTreg) (36). Another  group of Tregs named 
peripheral Treg (pTreg) or induced Treg (iTreg) develop in the periphery in response toT cell 
receptor (TCR) stimulation in combination with several other signals, including IL-2 and 
TGF-β (31, 37). Foxp3+ Tregs, by migration to inflammatory sites are responsible for the 
suppression of various effector cells. 
There is no well-accepted marker to distinguish tTregs from pTregs. Helios is a member of 
the Ikaros transcription factor family that has been considered as a marker of natural or 
thymic-derived Treg cells recently (38), although this notion has been challenged later on 
(39) and more recently additional roles for Helios has been suggested like a mediator of T-
cell homeostasis or a T-cell activation and proliferation marker (40, 41). 
Tregs exert their suppressive function by several modes of action that can be classified into 
five main mechanisms. Induction of suppressor cells or ‘infectious tolerance’ is mediated by 
TGFβ by induction of IL-10 expressing Tr1-like cells. IL-10, IL-35 and TGFβ are cytokines 
that are released by Tregs and have suppressive function. Tregs also can modulate APC cell 
function; for instance CTLA4 is a negative costimulatory factor that binds to CD80/CD86 (on 
APC) and mediates induction of indoleamine 2,3-dioxygenase (IDO), which is an 
immunosuppressive molecule made by DCs. Tregs can also mediate cytolysis by granzyme 
A, granzymeB and perforin. Metabolic disruption is the last proposed mechanism in order to 
induce suppressive function. CD25 (part of the IL-2 receptor) is a surface marker on Tregs 
that can deprive effector T cells of IL-2 (42, 43). Dysregulation in the function of Tregs 
contributes to the pathogenesis of many chronic inflammatory diseases and autoimmune 
diseases (44, 45). 
Tr1 and Th3 are other regulatory T cells with no Foxp3 expression. They have suppressive 
activity on effector cells by IL-10 and TGFβ production respectively (42). 
Other subsets of T cells 
In recent years the number of effector T helper subsets has grown further. Follicular helper T 
cells (Tfh), Th9 and Th22 are defined as distinctive T cell subsets but much still remains 
unknown about them. 
Recent studies suggest follicular helper T cells (Tfh) are a distinct lineage of CD4 T cells 
which act in the germinal center of peripheral lymphoid tissue where they provide help to 
maintain and to regulate germinal center B cell differentiation into plasma cells and memory 
B cells (46-48). Differentiation of Tfh cells is under control of Bcl6 as a master regulator and 
dependent on IL-21, IL-6 and STAT3. Human Tfh cells have been implicated in various 
diseases like immunodeficiency and autoimmunity (49). 
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Th9 is another newly described subset of T cells with preferentially production of IL-9. They 
develop from naive T cells in the presence of TGFβ and IL-4 (50, 51). GATA3 and STAT6 
are transcription factors and signal inducers that are required for Th9 differentiation. 
Involvement of Th9 cells in the pathophysiology of allergic asthma and autoimmunity has 
been demonstrated (52). 
Th22 is a new subset of T cells that by a unique gene expression pattern and function make it 
distinct from Th17 cells. The aryl hydrocarbon receptor (AHR) is an important transcription 
factor in Th22 cells and IL-6 and TNF are cytokines that promote Th22 differentiation. Th22 
cells, depending on the precise cytokine milieu and affected organ may modulate their 
functional profile showing both protective or pathogenic characteristics (53-55), and ongoing 
research aims to understand their complicated role in inflammatory and autoimmune diseases. 
 
 
 
 
Figure 1: T cell subsets differentiation. Following recognition of cognate antigen 
that is presented by APCs, naive CD4
+
 T cells become polarized into distinct 
effector T helper cell subsets in lymphoid organs. The cytokine milieu plays an 
important role in orchestrating T cell polarization. (adapted from Nature Review 
Immunology 12:136-148) (56). 
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T cell plasticity  
T cell plasticity is a phenomenon that has been recently described to occur in T cell subsets. 
Plasticity is defined as an ability of a T cell subset to display a flexible cytokine production 
pattern that includes cytokines normally considered to strictly belong to different T cell 
lineages. The most well-known example of a flexible T cell lineage was described in the case 
of Treg versus Th17 maturation, where TGFβ mediates differentiation of Foxp3+ Tregs from 
naive T cells in response to antigenic stimulation while the presence of TGFβ together with 
IL-6 leads to differentiation of Th17 cells from naive T cells (57). Among the T cell subsets, 
Th1 and Th2 cells cross-regulate each other by inhibiting the development of the other T cell 
subset, but following differentiation they have a stable phenotype and have achieved a 
lineage commitment state (58). In contrast, there is strong evidence indicating that a fraction 
of Foxp3+ Treg cells can acquire effector T cell function by losing Foxp3 expression under 
certain circumstances. The frequency of these ex-Foxp3+ Tregs increases particularly in the 
presence of inflammation (59). However, under inflammatory conditions a fraction of 
Foxp3+ Tregs can also acquire certain effector T cell functions such as IFNγ  production with 
retained Foxp3 expression (60). These regulatory T cells have a high level of Foxp3, lack of 
IL-2 production and a maintained suppressive activity (61). Transition of Th17 cells that 
predominantly produce IL-17 to IFNγ  producing cells has also been reported by different 
groups (62). The exact function of these flexible T cell subsets remains to elucidate but they 
may contribute to the protection against microbes, development of autoimmunity and anti-
tumor activity (63). Regarding Th9 cells with IL-9 production it is not clear whether they 
should be considered a distinct T cell lineage or if they reflect an adaptation of Th2 cells 
under certain circumstances. Flexibility and similarity between Tfh and both Th1 and Th2 
cells also makes it unclear whether Tfh is a separate T cell lineage or rather a 'chameleon' 
state of other subsets (64). 
1.4.2.2 CD8+ T cells 
CD8 T lymphocytes, named cytotoxic T lymphocytes (CTL), exert their main effect by 
killing target cells, such as virus-infected or tumour-transformed cells. CD8 T cells like CD4 
T cells have T cell receptors on their surface and they recognize peptide antigens which are 
presented by MHC class I molecules on the surface of infected cells. Following recognition 
of antigen by their TCR they are activated and they kill the target cells by delivery of granule 
proteins. Granzymes and perforins are two major components that CTLs release to kill target 
cells. Granzymes are enzymes that induce apoptosis in target cells and perforin is a delivery 
protein that mediates transfer of granzymes. CD8 T cells also carry Fas ligand on their 
membrane that can induce cytotoxicity by binding to Fas (CD95, a TNF receptor family 
member) which delivers a death signal if binds to its ligand).  Activated CTLs also have the 
ability to secrete many cytokines such IFNγ, TNF and IL-17 which are important in immune 
activation. CTL are critical T cells for eradication of intracellular pathogens like viruses (3). 
1.5 Antigen presentation and human leukocyte antigen (HLA) 
T cells can recognize cognate antigens by their surface T cell receptors, if antigens have been 
presented to them by major histocompatibility complex (MHC) molecules. Since the MHC 
molecules first were discovered on the surface of human leukocytes, they are also named 
human leukocyte antigen (HLA) complex. The MHC encoded genes in human are located on 
chromosome 6 as part of a locus which contains many genes which can classified in three 
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groups, named MHC class I, MHC class II and MHC class III. MHC class I and II are 
involved in presenting peptide antigens to T cells, while MHC class III contains genes for 
some cytokines and complement proteins and does not have any role in antigen presentation. 
Despite high similarity in the structure and function of MHC class I and II they also differ in 
many characteristics, and some of the major differences are summarized in table 1 (65, 66). 
 
 MHC class I MHC class II 
Source of antigen Endogenous antigens Exogenous antigens 
Responding cells CD8
+ 
T cells CD4
+
 T cells 
Composition of molecule α1, α2, α3/ β2 macroglobulin α1, α2/ β1, β2 
Encoded genes 
α chain encoded by MHC gene 
and β chain by non MHC genes 
Both α and β chain encoded by 
MHC gene 
Structure of molecule on 
cell surface 
Only α chain span the 
cell membrane 
Both α and β chain span the 
cell membrane 
Presented cells 
Expressed by most nucleated 
cells 
Expressed by APCs 
(Macrophage, DC and B cell) 
Peptide binding groove Both ends close Both ends open 
Size of presented peptide 8-10 amino acids 13-18 amino acids 
Table 1: Different characteristics of MHC class I and MHC class II molecules 
 
MHC class I encodes in humans the three genes HLA-A, -B and -C, while MHC class II 
encodes HLA-DP, -DQ and -DR. MHC allelic genes inherited from both parents are 
expressed equally. The gene region of MHC molecules is highly polymorphic and contains 
multiple gene variants with the same function and slightly different structure, for instance 
HLA-DRB1genes are encoded by 860 different allotypes (some are very common while 
others are very rare). This polymorphism leads to diversity in the expressed MHC repertoire 
and it is extremely rare to find two individuals with the same set of MHC molecules in the 
population (except for siblings) (1). 
1.6 The T cell receptor 
As described above, APCs present antigens via MHC molecules to the T cells. In order to 
induce appropriate immune responses against pathogens, the antigen should be recognized by 
specific cognate antigen receptors on the surface of T cells. T cell receptors like B cell 
receptors consist of a constant plus a variable domain, where the latter is antigen-specific and 
the enormous diversity of the total TCR repertoire enables T cells to recognize a wide variety 
of peptides.  
TheT cell receptor consists of an α polypeptide chain and a β polypeptide chain and each of 
them is composed of a variable and a constant region. The variable region of the TCR α chain 
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is encoded by V (variable) and J (junction) gene segments and the variable region of the β 
chain is encoded by V, D (diversity) and J gene segments. Each of these V, D and J segments 
can be selected from a number of alternative gene segments that after somatic gene 
rearrangement are combined to generate the complete variable α and β chains. This 
rearrangement creates vast diversity in variable regions of T cell receptors by the many 
different possible combinations of gene segments. 
The three dimensional structure of a T cell receptor in the antigen binding sites reveals 
hypervariable loops, named complementarity determining regions (CDR). T cell receptors 
have three different CDR loops on each chain, among them CDR3 has the most variable loop 
and make the center of the antigen binding site of a T cell receptor. It is formed by 
contributions of D and J gene segments of the α and β chains. A major part of TCR diversity 
is generated by random inclusion/deletion of nucleotides at the junctions between V, D and J 
segments (1, 3). 
A minority of T cells, termed γδ T cells, carry a different type of T cell receptor which 
instead of α and β chains is composed of γ and δ chains. These cells have completely 
different features compared to the αβ T cells and γδ T cells are part of the innate immunity 
system. 
1.7 T cell activation 
T cell maturation occurs in the thymus. During this process naive T cells expressing T cell 
receptors with capacity to recognize pathogenic antigens presented by MHC molecules 
develop following positive selection (to select T cells that recognize self MHC molecules by 
their T cell receptor) and negative selection (to eliminate T cells that bind to MHC with high 
affinity, a major mechanism to prevent autoimmunity) . Naive T cells leave the thymus and 
circulate between lymphoid organs to meet the cognate antigen presented by APCs. In order 
for activation of T cells to occur, antigen recognition by the T cell receptor is essential but it 
is not sufficient. In addition to T cell receptors a complex of co-receptors and co-stimulatory 
factors are necessary for proper T cell activation (67). 
The CD3 molecule (T cell specific marker) and ζ-chain are co-receptors that generate an 
activation signal upon peptide-MHC recognition by T cell receptors. T cell receptor, CD3 and 
ζ-chain all together make up the T cell receptor complex. CD4 and CD8 are two other co-
receptors expressed on the surface of T helper and cytotoxic T cells, respectively.  When T 
cell receptors recognize peptide and MHC complex, CD4 binds to MHC class II and CD8 
binds to MHC class I, ensuring that, depending on the antigen source, the correct type of 
effector cell is engaged. 
There are a couple of co-stimulatory receptors that are essential for T cell activation. CD28 is 
a co-stimulatory receptor that mediates initiating of the activation signal in naive T cells. 
CD28 binds to B7 (CD80 and CD86) molecules which are expressed on APCs surface (68, 
69). A group of integrin molecules are expressed on T cells, whose ligands are found on 
APCs. Leukocyte function-associated antigen-1 (LFA-1) is one of the important integrins 
which is involved in T cell activation and its ligand on APCs is intercellular adhesion 
molecule-1 (ICAM-1) (70). CD40 ligand (CD40L) on T cells is another molecule which 
indirectly participates in T cell activation. CD40L binds CD40 on the APC surface, inducing 
APCs to secrete cytokines like IL-12 (a cytokine that is necessary for Th1 cell differentiation) 
and enhancing expression of B7 molecules (71). There is also a set of negative co-stimulatory 
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molecules like CTLA-4 and PD-1 which promotes negative signals and inhibit T cell receptor 
signaling (72). CTLA-4 is a receptor that is expressed on the T cell surface and can bind to a 
B7 molecule instead of CD28 (73) (Figure 2). 
After antigen recognition by the T cell receptor and provided that necessary co-stimulatory 
signals are present, T cells initiate a process involving activation of biochemical signaling 
pathways and expression of a variety of proteins and transcription factors that leads to 
proliferation and clonal expansion, differentiation and obtaining full effector function. 
Activated effector T cells leave the peripheral lymph nodes and migrate to the site of 
infection or inflammation (74).   
 
 
 
Figure 2: T cell activation initiated by three signals. Signal 1 is mediated by T 
cell receptors that recognize antigens presented by MHC molecule. Signal 2 is the 
co-stimulatory signal, mainly mediated by triggering of CD28 by CD80 and 
CD86. Signal 3 is the polarizing signal that mainly is provided by various soluble 
or membrane-bound factors, such as interleukin-12 (IL-12) that promote the 
development of Th1 cells (adapted from Nature Review Immunology 3: 984-993) 
(75). 
 
1.8 The respiratory system 
The lung is the main organ of the respiratory system whose responsibility is to provide the 
body with oxygen and remove carbon dioxide. The respiratory system is divided into two 
major parts: the upper and lower parts. The upper respiratory tract (upper airway) consists of 
the nose, nasal cavity, mouth, pharynx, larynx. The responsibility of upper respiratory system 
is to provide proper air conditioning (humidity and temperature), particle removal and air 
filtration and also to activate the immune defense against pathogens. 
  11 
The lower respiratory tract consists of the trachea, bronchi, bronchioles and alveoli. The 
trachea enters the thoracic cavity and carries air from the throat into the lungs and vice versa. 
The trachea branches into bronchi and these are in each lobe of the lung further divided into 
smaller branches of airways called the bronchioles. Finally the bronchioles end into air sacs 
termed the alveoli. The alveoli have very thin walls surrounded by capillaries which permit 
exchange of gases with blood via passive diffusion; i.e. the main function of the respiratory 
system (Figure 3). 
 
 
 
 
Figure 3: The major features of the lower respiratory system including the 
trachea, bronchi, the bronchioles, and the alveoli. 
 
1.8.1 Immunology of the lungs 
The lungs have the largest epithelial surface of the body and according to their function they 
are constantly exposed to microorganisms and environmental irritants. The lung epithelium is 
an important physical barrier, which is the first line of defense and acts as a shield to protect 
the body against irritants and pathogens including airborne toxins, cigarette smoke, 
pollutants, bacteria and viruses. However, the lung epithelium is not only a physical barrier 
but also it is activated in response to pathogen exposure or environment-induced damage to 
secretion of antimicrobial peptides and inflammatory mediators to recruit immune cells to the 
site of infection or damage (76). 
The epithelium is composed of different cell types with a variety of functions which help the 
lung to protect itself against airborne insults. More than 50% of lung epithelial cells are 
named ciliated cells that by ciliary motility help mucous clearance (77). Goblet cells are 
another kind of epithelial cells that secrete mucous into the airway to trap pathogens and dust 
particles (78). The mucous layer in the airway is found from the trachea to the bronchioles 
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and it consists of a mixture of highly glycosylated mucin proteins that help to maintain lung 
health (79). In the smaller airways the secretory cells are replaced by Clara cells which are 
non-ciliated bronchiolar secretory cells. Clara cells have been shown to produce bronchiolar 
surfactants and specific enzymes to protect and support lung function (80, 81). Epithelial cells 
in alveolar walls and the ciliated epithelium also have pattern recognition receptors (PRRs) 
which can sense pathogens (82). 
In addition to these physiological barriers, the lung is recognized as a unique immunologic 
organ equipped to protect the body from inhaled invading pathogens. If the lung with specific 
physical and physiological clearance properties can’t control or remove inhaled particles, 
they can trigger the immune system in order to process foreign antigens. A variety of immune 
cells such as alveolar macrophages, lymphocytes and neutrophils are involved in lung 
protection. Alveolar macrophages account for approximately 95% of airspace leukocytes, 
lymphocytes with 1 to 4% and neutrophils only about 1% in the normal situation (82). 
The alveolar macrophage (AM) is the resident mononuclear phagocyte in the alveolar air 
spaces. AMs can directly phagocyte inhaled harmful particles, moreover they are not only a 
potent orchestrator in the presentation of antigen to the T cells, but also they release different 
mediators to activate and recruit other immune cells (83). The AM can also produce reactive 
oxygen and nitrogen species and proteolytic enzymes to kill the ingested pathogens (84). 
Neutrophils also have an important role in lung immunity to pathogens. Neutrophil 
infiltration should be under control and in chronic airway diseases persistence of neutrophils 
in the lungs may lead to tissue damage due to their cytotoxic function (85, 86). Different 
types of lymphocytes are found in the lungs of healthy individuals such as T cells, B cells, 
NK cells, γδ T cells. Dendritic cells are professional APCs which are present just below the 
airway epithelium and by migration from the airway mucosa to the thoracic lymph nodes play 
an important role in the activation of T cells (87). 
Insufficient or exaggerated immune responses to inhaled stimuli could lead to pathological 
conditions, such as pneumonia, asthma, chronic obstructive pulmonary disease (COPD) and 
interstitial lung disorders. Pulmonary inflammation affecting the airways or interstitium can 
be caused by many reasons and result in different manifestations. Both innate and adaptive 
immune systems have pivotal roles in orchestrating the inflammatory reaction and one of the 
most important cells in this process is T helper lymphocytes. Pulmonary inflammation is 
defined as increased inflammatory cells in the airspaces and lung tissue that are producing 
proinflammatory mediators such as hydrogen peroxide, interleukin-1 (IL-1), and interleukin-
8 (IL-8) (88). The pulmonary inflammation can lead to obstructive symptoms like in asthma 
and COPD where inflammation causes narrowing of the airways or it can result in a 
restrictive pattern like in interstitial lung disease where inflammation leads to increased lung 
stiffness. 
1.8.2 Interstitial lung diseases 
The interstitial lung diseases (ILDs), also called diffuse parenchymal lung diseases, are a 
diverse group of pulmonary disorders classified together because of similar clinical, 
physiologic, or pathologic features (89, 90). They can be caused by a variety of factors and 
are clinically characterized by diffuse infiltrates on the chest radiograph and histologically by 
distortion of the gas exchanging portion of the lung. The physiologic correlates are restriction 
of lung volumes and impaired oxygenation (91, 92). Idiopathic pulmonary fibrosis (IPF) (a 
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progressive and lethal fibrotic lung disease), nonspecific interstitial pneumonia, chronic 
beryllium disease, silicosis and sarcoidosis are examples of ILDs. 
1.8.2.1 Sarcoidosis 
Sarcoidosis is a systemic inflammatory disorder. It is characterized by non-caseating 
granulomas that most commonly affect the lungs. The pathogenesis of sarcoidosis includes 
the accumulation of lymphocytes and macrophages in the alveoli; thus involving innate as 
well as adaptive immune mechanisms. The prevalence of sarcoidosis is about 4.7-64 in 
100,000 and its incidence is about 1-35.5 in 100,000 per year. The northern European and 
African-American individuals have the highest rate of sarcoidosis (93, 94). 
Clinical aspects 
The main clinical symptoms in pulmonary sarcoidosis patients are non-productive cough and 
dyspnea, although other symptoms like fatigue (associated with impaired quality of life) and 
pain (especially arthralgia) are common in patients with pulmonary sarcoidosis (95, 96). 
Sarcoidosis can affect many different organs such as liver, spleen, lymph nodes, salivary 
glands, heart, nervous system; however the lung is the most commonly affected organ (97).  
In general, a radiographic staging system is used in order to classify patients with pulmonary 
sarcoidosis. In this system a normal chest radiograph is classified as stage 0, stage I shows 
bilateral hilar lymphadenopathy (BHL) without pulmonary infiltrates, stage II BHL with 
pulmonary infiltrates, stage III pulmonary infiltrates without BHL and stage IV fibrosis with 
distortions. The extent of pulmonary engagement, reflected through the chest X-ray 
classification, is associated with the prognosis (this is the case in 90% of patients) (97). 
Sarcoidosis patients generally have a rather good prognosis and nearly two-thirds of the 
patients recover spontaneously, however a chronic progressive disease course is seen in 
10%–30% of patients (98, 99). In late course of chronic disease, pulmonary fibrosis may 
occur in 20 to 25% of patients and the rate of mortality is 1%-5% among sarcoidosis 
patients(97, 100). 
Pathogenesis 
The aetiology of sarcoidosis is still not known. However, associations with environmental 
factors, genetic susceptibility and bacterial triggers have been reported (101, 102). Due to 
involvement of lungs, eyes and skin, environmental causes have been considered for many 
years. An association of sarcoidosis with exposure to irritants such as tree pollen, inorganic 
particles, and moldy environment has been reported (103-105). Occupational studies have 
shown an increased risk for sarcoidosis in people who work in U.S. navy, firefighting and 
metalworking (100, 106, 107). 
The presence of mycobacterial and propionic bacterial DNA in the lungs of sarcoidosis 
patients has been shown (108, 109). Accumulating data suggest that mycobacteria and in 
particularly M. Tuberculosis play a major etiologic role in sarcoidosis (110). It is not clear 
how infectious agents cause sarcoidosis, although one hypothesis is that sarcoidosis is caused 
by a viable, replicating mycobacterial or other infection with no microbiologic, pathologic 
and clinical evidence (111). However, most investigators favor a view of sarcoidosis as 
caused by remnants of an infectious agent in the form of poorly degradable antigens. The 
involvement of M. Tuberculosis in the pathogenesis of sarcoidosis has been validated by 
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immune assay studies (112). Ex vivo immune activation in response to several mycobacterial 
antigens have been studied and T cell responses to the mycobacterial virulence factor antigen 
85A (Ag85A), early secreted antigenic target protein-6 (ESAT-6), culture filtrate protein-10 
(CFP-10) and heat-shock proteins (hsp) have been reported in sarcoidosis patients (113-115). 
mKatG 
Homogenates of spleen and lymph node from sarcoidosis patients were previously used in the 
diagnosis of sarcoidosis. The test is named Kveim´s test and it is performed by intradermal 
injection of tissue homogenate that results, in sarcoidosis patients, in formation of 
granulomas at the site of injection (116). A proteomic approach was undertaken to identify 
antigens in sarcoidosis patients´ tissue samples, treated in the same way that Kveim´s reagent 
is prepared. Mycobacterium tuberculosis catalase-peroxidase (mKatG) was one of the non-
self tissue antigens identified and antibodies to recombinant mKatG were detected in the sera 
of 12 of 25 (48%) sarcoidosis patients (117). This finding indicated that mycobacterial 
antigen is present, at least in a subset of sarcoidosis patients (112). T cell responses against 
mKatG have been observed in sarcoidosis lung and peripheral blood mononuclear cells (118, 
119), and a study on lung mKatG-reactive, IFNγ-producing effector T cells indicated that T 
cell responses to mKatG in sarcoidosis are regulated in a manner expected for a pathogenic 
antigen (120). 
Immunopathogenesis  
Non-necrotizing granulomas are the histological hallmark of sarcoidosis. The granuloma 
formation occurs in the body whenever an antigen cannot be completely eliminated or 
degraded by macrophages. In this situation macrophages and epitheloid cells fuse together 
and make multinucleated giant cells; moreover accumulation of activated mononuclear cells 
(mostly T cells) and interaction between innate and adaptive immune cells by release of 
proinflammatory cytokines orchestrates the formation of granulomas and induce an immune 
stimulation in the affected organ (121-123) (Figure 4).  
In bronchoalveolar fluid of sarcoidosis patients the proportion of T cells is increased (20–
60% of the total cell count) with dominance of CD4+ T cells. An increased CD4/CD8 ratio in 
bronchoalveolar fluid of patients (>3.5) is one of that characteristics of sarcoidosis patients 
(124). The accumulated activated CD4+T cells in alveoli are typically Th1 cells and they are 
considered to be of central importance for the inflammatory process, although CD4+ T cells 
in lung tissue and bronchoalveolar cells bearing a phenotype consistent with Th17 
polarization and persistence of Th17 cells in sarcoidosis patients has been observed (125-
127). By contrast, Th2 cell responses (IL-4 and IL-5 secretion) are downregulated at sites of 
inflammation in sarcoidosis patients (128, 129). 
T cells in BAL fluid of sarcoidosis patients are highly activated and they express activation 
markers like CD69 and HLA-DR. A Th1 cytokine signature i.e. IFNγ is highly expressed, 
moreover cytokines that promote a Th1 response such as IL-12, IL-18 and IL-27 are 
upregulated in the lung of sarcoidosis patients (127, 130, 131). The expression of Th1-
associated chemokine receptors such as CXCR3 and CCR5 has also been reported in lung of 
sarcoidosis patients (132). 
 
 
  15 
 
 
Figure 4: Schematic speculation process of granuloma formation in sarcoidosis 
patients (Adapted from (133) with minor modification). 
 
Treatment  
There is no cure for sarcoidosis but conventional treatment improves the clinical 
consequences of disease by alteration of the granulomatous process (134). The decision of 
which treatment to use is dependent on clinical characteristics and severity of disease (135). 
Spontaneous resolution has been observed in many patients and treatment can usually be 
avoided, but oral corticosteroids are usually prescribed in patients with pulmonary sarcoidosis 
who suffer from lung dysfunction and persistent pulmonary infiltrates. The first line of 
treatment in severe sarcoidosis is corticosteroids (98, 136). There are other strategies in 
treatment of sarcoidosis patients such as cyclosporin to inhibit  activated T cells or TNF 
blockade given the importance of TNF in the initiation and perpetuation of the granulomatous 
process, although there is no consensus regarding the  efficiency of these treatments and their 
effect varies in different patients (137-139).  
Löfgren’s syndrome  
Sarcoidosis patients display phenotypic heterogeneity. A subgroup of sarcoidosis patients 
with specific clinical features, described the first time by the Swedish pulmonary physician 
Sven Löfgren (1910-1978), are said to have Löfgren’s syndrome. Löfgren’s syndrome (LS) is 
an acute form of sarcoidosis with bilateral ankle arthritis and/or erythema nodosum, usually 
fever, and bilateral hilar lymphadenopathy (140, 141).Löfgren´s syndrome has a good 
prognosis in general and spontaneous recovery within two years is particularly common in 
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Löfgren´s syndrome patients who also express the HLA allele DRB1*0301 (DR3) (142). 
HLA-DR3+  patients (two thirds of which have LS) virtually always have accumulations of 
TCR V2.3+ CD4+ T cells, i.e. T cells with a particular T cell receptor (TCR) alpha chain 
variable gene segment (AV2S3) (TCR-AV2S3) in the lungs (143). Such expansions were not 
found in DR3+ healthy individuals or in patients with other inflammatory pulmonary 
disorders (144, 145). More recently, these V2.3+ T cells in DR3+ patients were found to 
often use V22 as part of their TCR chain (146)(Kaiser et al, unpublished observations). 
The reasons for spontaneous recovery in some patients and disease progression in others 
remain to be elucidated. However, hypothetically in non-necrotising granuloma remnants of 
an assumptive antigen are not fully degraded and antigen persistence leads to progressive 
chronic disease (122, 147). In contrast, it can be hypothesized that the immune responses in 
patients with spontaneous resolution results in complete elimination of causative antigen 
(134). 
1.8.3 Smoking induced-inflammation 
Cigarette smoking by more than one billion consumers in the whole world is one of the most 
challenging health issues due to its effect on lung and other organ systems resulting in a high 
morbidity and mortality (148). Cigarette smoke consists of more than 6000 different 
chemicals and toxic components, such as nicotine, aromatic hydrocarbons, dioxin, tobacco 
glycoprotein, phenol, metals and ions which some of them are cytotoxic, antigenic and 
carcinogenic (149-151). Tobacco smoking is a well-known key factor in the pathogenesis of 
several diseases, such as infection, lung cancer, cardiovascular diseases, COPD and 
autoimmune disorders.  
Cigarette smoke influences the airways by directly inducing activation of epithelial and 
immune cells. Cigarette smoke influences both innate and adaptive immunity at the local or 
systemic levels in different ways (151). The chronic exposure to components of cigarette 
smoke triggers a variety of pulmonary or systemic immune responses. Smoking can induce or 
inhibit release of both inflammatory and anti-inflammatory cytokines and mediators (151). 
Cigarette smoke through up-regulation of NF-κB (152) can induce secretion of inflammatory 
cytokines such as TNF, IL-1, IL-6, IL-8 and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (153, 154). Induction of pro-inflammatory mediators leads to recruitment 
of immune cells and consequently inflammation. However, cigarette smoke can also down-
regulate the release of IL-1β, IL-2, IFNγ and TNF via toll like receptors (155). Nicotine is 
one of the components of cigarette smoke that show direct anti-inflammatory effect by 
diminishing IL-6 production (156). Furthermore nicotine can activate α7 nicotinic 
acetylcholine receptor that leads to down-regulation of pro-inflammatory cytokines like TNF, 
IL-1b and IL-6 (157). Cigarette smoke by different mechanisms modulates epithelial and 
immune cell signaling to induce suppression of aspects of innate and adaptive immune cell 
activation which hinder immunity to infection (158, 159). 
T helper lymphocytes at the center of adaptive immunity have a pivotal role in orchestrating 
the host defense and inflammatory reaction following triggering by specific antigens. 
Smoking has an influence on different T cell subsets with specific inflammatory or anti-
inflammatory cytokine properties. Imbalance between pro-inflammatory and anti-
inflammatory cytokines in the lungs can result in pathologic inflammatory conditions.  
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Smoking-induced autoimmunity 
Cigarette smoking has been shown to be associations with autoimmunity. There is strong 
evidence of an increase in prevalence of many autoimmune diseases such as rheumatoid 
arthritis, systemic lupus erythematous, Crohn's disease and systemic sclerosis in smokers 
(151, 160, 161). 
Rheumatoid arthritis (RA) is an autoimmune disorder and a striking example of gene-
environment interaction as the combination of smoking history and having two copies of 
HLA-DR “shared epitope” genes increased 21-fold the risk of the RA form characterized by 
antibodies to citrullinated protein antigen (ACPA) (162). Part of the mechanism appears to be 
that cigarette smoke induces the PAD enzymes responsible for citrullination (a post-
translational modification) of proteins such as vimentin (163). Further examples of 
autoimmune disorders where cigarette smoking plays a role are systemic lupus erythematosus 
(SLE), where a smoking history was associated with more active disease and increased levels 
of anti-dsDNA antibodies (164). 
Smoking-induced multiple sclerosis 
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS), characterized by multifocal demyelination of nerves with relative preservation of 
axons and accompanied by oligodendrocyte loss  (165-168). T-cells have a central role in the 
pathophysiology of MS and presence of T cells in CNS lesions and infiltrates of T-cells 
throughout the CNS is a hallmark characteristic in all stages of MS patients (169). Activated 
T-cells occur at a higher frequency in peripheral blood of MS patients (170). 
The risk of developing multiple sclerosis (MS) is strongly influenced by smoking in 
individuals with genetic susceptibility (certain HLA alleles). An interaction between the 
presence of HLA-DRB1*15 and absence of HLA-A*02 among smokers leads to a 17-fold 
increased risk of MS compared with non-smokers without the genetic risk factors. 
Furthermore the risk increased further when the analysis was restricted to comparing current 
smokers with never-smokers (171). Smoking is associated with increased lesion volume and 
greater atrophy in MS patients (172). 
Importantly, there is strong evidence in Lewis rat transfer experimental autoimmune 
encephalomyelitis (EAE) (a model of MS) that shows that the lung could contribute to the 
activation of potentially autoaggressive T cells and their transition to a migratory mode as a 
prerequisite to entering the central nervous system (CNS) (173). 
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2 AIMS 
T cells of different subsets have a pivotal role in orchestrating the host immune protection 
and inflammatory reaction. Activated T cells in the lungs not only have the potential to affect 
that particular organ but due to lymphocyte trafficking they can also contribute to immune 
responses in other organs. The overall aim of the studies presented in this thesis was to 
investigate the characteristics of T cell immunity in chronic pulmonary inflammation in two 
different aspects: 
A. Investigation of antigen-specific T cell responses in patients with pulmonary 
sarcoidosis. Project number 1 and 2 were done based of this objective. 
 To elucidate the ability of T helper 1 cells in lung and blood of different sarcoidosis 
patient subgroups to respond with cytokine production to mycobacterial antigen 
(mKatG) stimulation,  
 To study the single- or multifunctional cytokine profile of Th1 cells in response to 
mycobacterial antigen in the lung and blood of sarcoidosis patients. 
 To evaluate the presence and levels of IL-17 and the frequency of IL-17 producing 
cells in response to mKatG and PPD in the lung and blood of patients with active 
sarcoidosis. 
 To compare levels of IL-17 and the frequency of antigen specific IL-17 producing 
cells in lung and blood of different sarcoidosis patient subgroups. 
B. Determining how smoking affects lung T-cell immunity, with regard to the influence 
of smoking in developing autoimmune disease 
 
 To characterize of effector and regulatory T cell subsets in the lungs and blood of 
smoking and non-smoking healthy individuals. 
 To elucidate the effector and regulatory T cell subsets in the lungs and blood of 
multiple sclerosis patients with regards to effect of smoking and treatment. 
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3 COMMENTS ON METHODOLOGY 
The present thesis is based on studies of human samples from the airways and blood of 
sarcoidosis patients, MS patients and healthy individuals (smokers and non-smokers). The 
studies were performed after approval by the Regional Ethical Review Board (Stockholm, 
Sweden) and written consent was obtained from the all included subjects. 
3.1 Study subjects 
The sarcoidosis patients included in the present study were referred to the Lung and Allergy 
Clinic at the Karolinska University Hospital, Solna, Stockholm, Sweden for primary 
diagnostic investigation. The diagnosis was established using the criteria of the World 
Association of Sarcoidosis and other Granulomatous Disorders (WASOG) (97), based on 
chest radiographic picture, pulmonary function tests (vital capacity, forced vital capacity, 
forced expiratory volume in one second, and diffusing capacity of the lung for carbon 
monoxide), histology (positive biopsies), bronchoalveolar lavage (BAL) findings, and clinical 
symptoms compatible with sarcoidosis. 
The clinical examinations of MS patients who participated in this study were performed by 
specialists in the Neurology clinic at the Karolinska University Hospital in Solna, Stockholm, 
Sweden and all patients diagnosed with MS fulfilled the McDonald criteria revised in 2010 
(174). All MS patients were evaluated clinically at the time of sampling with the Expanded 
Disability Status Scale (EDSS). After diagnostic evaluation at the Neurology clinic, all 
patients were referred to the Lung and Allergy clinic for primary clinical examination with 
respect to the lungs and spirometry. 
All healthy subjects in this study were examined at the Respiratory Medicine Unit 
(Karolinska University Hospital, Solna, Stockholm, Sweden). Included individuals had 
normal lung function and were in good health. They had normal chest X-rays and there were 
no signs of respiratory infection for at least one month prior to the bronchoscopy procedure.  
DNA extraction was routinely done from whole blood of all subjects and PCR was run for 
analysis of HLA-DR by Olerup SSP™ PCR (Sequence Specific Primers for PCR). 
3.2 Sampling 
Bronchoalveolar lavage 
Patients underwent bronchoscopy with bronchoalveolar lavage (BAL) in the morning. 
Morphine-scopolamine was injected intramuscularly, and topical anesthesia was sprayed into 
the nose and throat immediately before the BAL procedure (175). BAL was performed 
during flexible fiberoptic bronchoscopy after wedging the bronchoscope in a middle-lobe 
segmental bronchus. Sterile phosphate-buffered saline (PBS) solution was instilled in five 
aliquots of 50 mL. The solution was gently aspirated into a plastic bottle and kept on ice until 
use. In the laboratory, the BAL fluid was filtered to remove debris and mucus and the 
recovered volume was determined. BAL cells were washed two times with cold PBS and 
finally total cell number was determined by Bürker chamber counting. 
The BAL cell differential count, including percentages of macrophages, lymphocytes, 
neutrophils, eosinophils, basophils and mast cells, was determined using May-Grünwald-
Giemsa staining of cytospin slides. 
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Peripheral blood mononuclear cells 
Whole blood was obtained in the morning of bronchoscopy and collected in heparinized 
tubes. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque 
density gradient separation (Pharmacia, Uppsala, Sweden). Equal volumes of blood and 
room-tempered (RT) phosphate buffered saline (PBS) solution (pH 7.4) were mixed and 
gently transferred to tubes containing Ficoll-Paque
TM
 Plus. The tubes were centrifuged (400g 
for 25 min at RT) and thereafter PBMCs formed a whitish layer just beneath the plasma. The 
PBMCs were carefully transferred into a new tube and washed 2 times with cold PBS. After 
last washing PBMCs were counted in a Bürker chamber in order to obtain the total cell 
number. 
3.3 Methodology 
T cell stimulation 
T cell stimulation was done in order to evaluate T cell cytokine production. We have used 
different agents for T cell stimulation depending on the specific aims. In paper I, T cell 
stimulation was done by mKatG, purified protein derivative (PPD) from Mycobacterium 
tuberculosis and superantigen stimulation. The recombinant mKatG protein was isolated 
and prepared at the John Hopkins University School of Medicine, using an Escherichia coli 
strain (176). PPD is an extract of Mycobacterium tuberculosis PPD and it is widely used as 
a diagnostic antigen for tuberculosis by skin test. A total of 171 different proteins have been 
identified in the PPD mixture. PPD is commonly used for in vitro stimulation to 
characterize B and T cell reactions (177). We have also used a mixture of Staphylococcus 
enterotoxin A (SEA) and Staphylococcus enterotoxin B (SEB) as a positive control in our 
experiments (superantigens). Superantigens are bacterial or viral proteins with the ability to 
bind simultaneously to the α chain of HLA class II and a Vβ chain from the T cell receptor. 
Each superantigen has specificity for several of the Vβ versions. Superantigens are potent 
mitogens and powerful tools for T cell stimulation (178). A mixture of SEA and SEB thus 
in a physiological way has the potential to stimulate a large fraction of T cells. 
During antigen stimulation, whole blood cells were further co-stimulated with anti-CD28 
and anti-CD49d. Unstimulated BAL cells in medium alone and unstimulated whole blood 
were used as negative controls. 
Brefeldin A (BFA) (GolgiPlug derived from Penicillum) is a protein transport inhibitor and 
was added to stimulated cells in order to block the intracellular protein transport process. It 
was added to the BAL and blood samples during the last 4 hours of in vitro antigen 
stimulation. Following T cell stimulation cytokine production was evaluated by flow 
cytometry. 
In paper II, T cell stimulation was done in order to study mKatG specific Th1 and Th17 
responses by Elispot. 10 μg/ml mKatG was used for T cell stimulation and anti-CD3 as a 
polyclonal stimulation was used as a positive control for stimulation of Th17 cells and 
Phytohemagglutinin (PHA) for Th1 stimulation. 
In paper III and IV, intracellular cytokine and transcription factor staining was analyzed by 
flow cytometry. We stimulated both BAL and PBMC by anti-CD3 together with anti-CD28 
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in 37°C, humidified atmosphere of 5% CO2
 
in air and unstimulated BAL and PBMC cells 
in medium alone were used as negative controls. Protein transport inhibitor (Brefeldin A) 
was added to the cells after 4 hours incubation followed by 12 hours incubation for a total 
of 16 h incubation. Stimulation in presence of Golgi Plug in cell culture for longer than 12 
hours is lethal for the cells. 
Flow cytometry 
Flow cytometry was done on BAL cells, whole blood samples and PBMC for the study of 
phenotype and intracellular markers of T cells. A FACS Canto II (BD, Sweden) flow 
cytometer with filters to analyze eight colors was used. 
The cell surface markers CD3, CD4 and CD8 were used to delineate T cell subsets in both 
BAL and blood. In paper I and II the study was done on samples from sarcoidosis patients, 
and staining of TCR AV2S3 was also performed in order to determine the frequency of T 
cells whose T cell receptors have this fragment in their variable region of the α chain. CD3, 
CD4, CD8 and TCR AV2S3 staining is part of the routine BAL evaluation which is 
performed on all sarcoidosis samples in Lung Research Lab. A CD4/CD8 ratio greater than 
4 supports the diagnosis of sarcoidosis (179). Study of AV2S3 expression is one practical 
way to predict who are DRB1*03 positive before the results of HLA typing are obtained 
(180), since this is the case in virtually all patients who have an expansion of T cells with 
TCR AV2S3 in BAL (greater than 10.5% of CD4+ cells) (3 times the median frequency of 
TCR AV2S3+ cells in blood CD4+ T cells of normal healthy individuals). In paper II and 
IV all samples were stained with aqua fluorescent reactive dye (Live/Dead fixable dead cell 
stain kits, Invitrogen, USA) in order to discriminate between live and dead cells 
populations. 
Intracellular cytokine staining was performed on both BAL and blood samples to evaluate 
cytokines and transcription factors. Following surface staining, fixation and 
permeabilization were performed on BAL and blood samples, thereafter intracellular 
staining was done for the cytokines and transcription factors of interest. Percentages of T 
cell subsets expressing the various markers were determined. The median fluorescence 
intensity (MFI) for cytokines and transcription factors was calculated in order to indicate 
the quantitative amount of each marker per cell (181). Matched isotype controls were used 
for each cytokine and transcription factor to discriminate specific antibody staining from 
non-specific background staining. 
Elispot 
In paper II, Elispot assay was performed on PBMC and BAL cells from sarcoidosis patients 
and on PBMC from healthy controls for detection of IFNγ and IL-17 following mKatG 
stimulation. Elispot plates were treated with 70% ethanol. Thereafter plates were coated with 
anti-IFNγ coating antibody or anti-IL-17 coating antibody (Mabtech, Sweden) overnight. 
After washing, plates were blocked with complete tissue culture medium (CTCM) for 2 h at 
room temperature and freshly obtained PBMC (3×10
5
) or BAL cells (2×10
5
) were added to 
each well. Alveolar macrophages of BAL samples were partly depleted by plastic adherence 
during one hour incubation before adding the samples to the Elispot plate. Cells were 
stimulated with 10 μg/ml mKatG. Phytohemagglutinin (PHA) and anti-CD3 monoclonal 
antibody were used as positive controls for IFNγ and IL-17 respectively and unstimulated 
cells were used as negative control. Cells were incubated at 37 °C in a humidified atmosphere 
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of 5% CO2 for 16 h during which secreted cytokines were captured by the coating antibodies. 
Subsequently, biotinylated IFNγ monoclonal antibody or biotinylated anti-IL-17 monoclonal 
antibody were added and samples incubated for 2 h, thereafter plates were incubated with 
streptavidin–alkaline phosphatase for 1 h. Finally substrate (BCIP/NBT, Mabtech) was added 
and plates were developed for 10–20 min. We applied extensive washing between each step 
and after the last washing and overnight drying, plates were scanned and counted using the 
Elispot Reader system with AID Elispot Software 4.0. Results are presented as a mean value 
of triplicate wells and normalized to spot forming cell (sfc) in one million cells. 
Fluorospot analysis of IFNγ and IL-17 producing cells was done on some samples.  
Following labeling and coating of theIPFL plate©, cells werestimulated with mKatG. 
Secreted IFN-γ and IL-17 were captured and then stained with antibodies labeled with green 
and red fluorophore (FITC and Cy3). The plate was analyzed by an automated reader with 
filters for FITC and Cy3. The ability to detect cells that produce both cytokines 
simultaneously is the biggest advantage of Fluorospot compared to Elispot.  
Quantitative immune PCR 
The level (ie. concentration) of soluble IL-17 protein was measured in the cell-free BAL 
fluid of sarcoidosis patients with Löfgren’s syndrome (DR3+ and DR3-), sarcoidosis 
patients without Löfgren’s syndrome and healthy individuals. Due to the low absolute 
concentration of extracellular IL-17 protein in the diluted sample caused by the BAL 
procedure per se, we utilized a customized quantitative immuno-PCR (qIPCR) technology 
developed in A. Lindéns laboratory in collaboration with TATAA Biocenter™ (Göteborg, 
Sweden) (182). This qIPCR combines the high specificity of Enzyme-linked 
immunosorbent assay (ELISA) with the high sensitivity of quantitative PCR for detection 
of low concentrations of protein antigens (183). Plates were coated with anti-human IL-17 
antibody and after blocking, 20 times concentrated BALF using ultrafiltration from each 
individual were added in triplicate. Thereafter each well was incubated with a detection IL-
17 antibody/DNA conjugate (conjugated at TATAA Biocenter™; detection antibody from 
eBioscience™). A dilution series of recombinant human IL-17 was added to separate wells 
in triplicate and incubated in the same way as the samples for obtaining a standard curve. 
Real-time PCR was carried out by specific primers. After extensive washing, Ct values 
were determined for individual samples. The mean values of triplicate determinations were 
calculated after comparisons with a standard curve. 
Immunohistochemistry 
In order to visualize the expression of IL-17 in lung tissue from sarcoidosis patients we 
performed immunohistochemistry (paper III). Contiguous 4 μm thick transbronchial 
paraffin-embedded sections from sarcoidosis patients (patients with and without Löfgren’s 
syndrome) and healthy controls were deparaffinised in xylene and rehydrated by gradient 
ethanol. Antigen retrieval was done by boiling slides in citrate buffer (pH 6.0). After 
elimination of the endogenous peroxidase activity in the 0.3% H2O2, blocking was done by 
5% goat serum. Rabbit polyclonal anti IL-17 as primary antibody was used for IL-17 
staining. The staining was performed in parallel with rabbit IgG isotype control and tonsil 
tissue was processed as the positive tissue control. Thereafter slides were treated with 
biotinylated secondary antibodies (goat anti-rabbit). The staining continued with Vectastain 
Elite ABC Kit and the immune reaction was visualized using 3,3′-diaminobenzidine. 
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Sections were then counterstained with Mayer's hematoxylin, dehydrated, mounted and 
viewed under light microscope at a magnification of ×100, ×200 and/or ×400. 
Statistical analysis 
Statistical analysis of the data was performed by GraphPad PRISM 5.02 (GraphPad Software 
Inc., San Diego, CA, USA). Mann–Whitney U test or unpaired t-test was used for 
comparisons between two groups (non-parametric or parametric values, respectively). 
Analysis of data for more than two groups was performed by one-way ANOVA test and 
followed by Dunn’s or Tukey’s post-test for non-parametric or parametric values 
respectively. Wilcoxon signed rank test was used for comparisons of dependent samples. 
Correlation analysis was performed by Spearman’s rank correlation test. A p-value of less 
than 0.05 was considered to define statistical significance. 
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4 RESULTS AND DISCUSSION 
 
4.1 Antigen-specific Th1 responses in sarcoidosis (Paper I) 
Sarcoidosis is a multisystem granulomatous disease of unknown cause with commonly 
prominent lung involvement. Clinical manifestations of sarcoidosis vary from an 
asymptomatic state to a life-threatening condition (184). T cells are known to play a critical 
role in the pathogenesis of this disease and accumulation of activated CD4+ T cells in the 
airways of patients has been well documented. Given the increased levels of IFNγ and IL-2 in 
the lungs of sarcoidosis patients, it has been postulated that sarcoidosis is a Th1 mediated 
disease (185-187). However, accumulating data supports the importance also of other T cell 
subsets in the pathogenesis of sarcoidosis. The etiology of sarcoidosis is still unknown, 
although it has been proposed that mycobacterial species are involved in the pathogenesis of 
at least a subgroup of sarcoidosis patients (188). A specific mycobacterial antigen, 
mycobacterial catalase–peroxidase (mKatG) has been detected in sarcoidosis tissue. 
Furthermore, mKatG has been shown to trigger B and T cell responses in lung and blood 
cells of sarcoidosis patients (118-120). Here we wanted to investigate in detail Th1 and Th17 
responses to mKatG in BAL and blood T cells from subgroups of sarcoidosis patients with 
distinct clinical manifestations. 
Sarcoidosis patients enrolled in this study were classified as patients with Löfgren’s 
syndrome (LS) and patients without Löfgren’s syndrome. In addition, all patients with LS 
were selected to be HLA-DR3+ (DRB1*0301) and with an accumulation of CD4
+
 TCR 
AV2S3
+
 BAL T cells (n=13). In a sharp contrast all non Löfgren’s syndrome patients should 
in addition fulfil the criterium to be  HLA-DR3- (n=10). Since Löfgren´s syndrome in 
combination with HLA-DR3+ predicts the most favorable prognosis (140), we selected these 
two groups and hypothesized that they would reflect opposite ends of the “prognostic 
spectrum” in sarcoidosis. In particular HLA-DRB1*14 and –DRB1*15 alleles are strongly 
associated with a chronic disease course, at high risk of developing pulmonary fibrosis (141, 
142). 
IFNγ and TNF are important cytokines in mycobacterial clearance (189-191) and IL-2 is 
involved in T cell clonal proliferation (192). All three cytokines can be produced by CD4+ 
and CD8+ T cells. We selected these three cytokines to evaluate the production of each in 
response to mKatG in sarcoidosis patients. 
Stimulation with mKatG led to activation of BAL and blood CD4+ T cell cytokine responses 
in both Löfgren’s and non Löfgren’s syndrome patients when compared to spontaneous 
cytokine production i.e. un-stimulated sample.  
An important role of Th1 cells and related cytokines in protection against M. tuberculosis has 
been reported by different groups. Splenocyte T cells from (Bacillus Calmette–Guérin) BCG 
immunized mice could adoptively induce protection and control growth of M. tuberculosis in 
recipient mice (193). Although IFN-γ alone is insufficient to control M. tuberculosis 
infection, it is required for protection against M. tuberculosis and an early response of IFNγ 
producing T cells is critical to induce resistance to infection with M. tuberculosis (194, 195). 
The requirement for TNF in control of M. tuberculosis infection is complex, e.g. it has a role 
as a mediator of macrophage activation. Moreover TNF in synergy with IFNγ induces nitric 
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oxide synthase-2 expression (Absence of NOS2 causes increased susceptibility to M. 
tuberculosis infection (196). TNF in M. tuberculosis infection is also involved in cell 
migration and cell localization within lungs. It also affects formation of functional 
granulomas in infected tissues by influencing the expression of adhesion molecules, 
chemokines and chemokine receptors (197). 
CD8+ T cells in sarcoidosis patients exhibited a cytokine profile similar to CD4+ T cells 
following mKatG stimulation. Our data regarding responses of CD4+ and CD8+ T cells to 
mKatG is in accordance with a previous study showing positive IFN response after mKatG 
stimulation in U.S. patients (120). 
Since MHC class I presentation is most efficient with cytoplasmic antigens, a possible role 
for CD8
+
 T cells in the immune response to M. tuberculosis received little attention for many 
years, since mycobacterial antigens are normally restricted to phagosomes and presented on 
MHC class II to CD4+ T cells (197). However, mice with a genetic deficiency in β2 
microglobulin, and thus deficient in MHC class I molecules were quite susceptible to M. 
tuberculosis infection (198). There is strong evidence that indicated migration of CD8+ T 
cells to the lungs in M. tuberculosis infection occurs with the same kinetics as that of CD4+ T 
cells (199) and these CD8+ T cells are capable to produce IFNγ and to lyse infected 
macrophages (200). Rapid accumulation of CD8+ T cells in the lung of mice infected with M 
tuberculosis has been reported before (201).  
Both CD4+ and CD8+ T cells are capable to release cytokines and mediators to activate 
macrophages. Our data on the cytokine profile of CD8+ T cells indicated that CD8+ T cells 
not only contribute in cytotoxic activity but also that they are activated to cytokine production 
and to protect against M. tuberculosis. CD8+ T cells are found within granulomas and can 
help to prevent spreading of mycobacteria (202). Although the relative frequency of CD8
+
 T 
cells in BAL of sarcoidosis patients is reduced at onset, their relative proportion increases at 
later stages of disease. Our data suggests that both CD4+ and CD8+ T cells play an important 
role in mycobacterial clearance, which is also supported by other studies (203). 
Comparing T cell activity in response tomKatG between BAL and blood demonstrated that 
BAL T cells responded to mKatG with higher IFNΓ production than blood T cells in both 
Löfgren’s and non Löfgren’s patients. This indicated that mKatG specific T cells are 
accumulated in the affected organ. Moreover, it has been shown that alveolar T cells in 
sarcoidosis patients are more activated than peripheral cells (204).   
We didn’t compare BAL T cell reactivity to mKatG with irrelevant antigens in sarcoidosis 
patients. However, reactivity of BAL cells from sarcoidosis patients to mycobacterial antigen 
but not to Keyhole Limpet Hemocyanin has been shown by others (118, 205). Furthermore, T 
cell responses in blood of most sarcoidosis patients to mycobacterial antigen but not lysate 
from Trypanosoma brucei have been demonstrated by other groups (206). 
In contrast to mKatG responses, IFN responses to PPD was observed only in CD4+ T cells, 
and not in CD8+ T cells, which indicates that there might be a selective recognition of the 
mycobacterial epitopes among T cells. Some mKatG-derived peptides may be constituents of 
PPD, but if so they would clearly form a small fraction of the whole protein mixture. 
There were no major differences between patient subgroups regarding the production of 
individual cytokines in response to mKatG and PPD. 
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Among the T cells some can exhibit a multifunctional capacity, i.e. secrete two or more 
cytokines. As we mentioned before IFNγ and TNF are two important cytokines for 
combating mycobacterial infections. (189, 190, 194, 207). When combined, IFN and TNF 
synergize in their capacity to mediate effective killing (208, 209). There is some evidence that 
shows T cells secreting IFN, TNF and IL-2 simultaneously were found to possess the best 
protective capacity towards Mycobacterium tuberculosis (210). 
We therefore investigated multifunctional T cells, i.e. CD4+ and CD8+ T cells that 
simultaneously produce two cytokines in response to mKatG and PPD. Among CD4+ and 
CD8
+
 T cell subsets, we calculated the percentage of total mKatG-reactive cells that produced 
single IFN, single TNF, or IFN and TNF in combination (the same calculation was made 
for IFN in combination with IL-2). We found that mKatG stimulated the BAL CD4+ T cells 
to less single IFN production, but more simultaneous production of IFN and TNF, in 
patients with Löfgren´s syndrome as compared to non-Löfgren´s syndrome patients. In 
contrast, PPD stimulation gave rise to similar cytokine pattern in both patient subgroups. This 
finding suggests that DR3+ sarcoidosis patients with Löfgren’s syndrome i.e. patients with 
favorable prognosis have a more potent immune response towards a minor number of 
antigens, in which mKatG could be one of them, which consequently could lead to antigen 
elimination followed by recovery. We may speculate that patients with non-Löfgren´s 
syndrome have a less potent response to mKatG and other antigens, allowing antigen 
persistence. Additionally, they may exhibit an epitope spreading within the lungs, leading to 
involvement of more antigens and more IFN production with solid inflammation and 
prolonged disease, since analysis of total CD4+ T cell IFNγ mRNA expression showed 
higher levels in DR3- patients (211). 
The median fluorescence intensity (MFI) of cytokine staining was measured in patients with 
Löfgren´s syndrome. The MFI value is an indication of the quantity of cytokine content on a 
per-cell basis (212). Our findings demonstrated that the multifunctional CD4+ T cells i.e. 
IFNγ/TNF double producing cells, following mKatG stimulation, had the highest MFI values 
of each cytokine, suggesting that they produce more of the two respective cytokines from 
each cell, compared to single cytokine-producing CD4+ T cells and it indicates these 
multifunctional T cells have a more potent effector capacity with regard to each respective 
cytokine. Seder et al. have reported the importance of a potent and durable T cell response 
with a high frequency of T cells that are antigen specific in vaccine development (213). The 
frequency of IFNγ producing cells is the most common parameter used to evaluate vaccine 
responses due to the important role of IFNγ in pathogen clearance (190, 214). However, 
IFN-producing T cells are not sufficient for protection (215, 216) and presence of TNF is 
also important to induce protection. The role of TNF in immunopathology of tuberculosis is 
complex. Rheumatoid arthritis patients who were treated with anti TNF antibody were 
susceptible to developed fatal tuberculosis(217) which indicated the importance of TNF in 
protection against infection. The contribution of both IFNγ and TNF lead to enhanced killing 
of M. tuberculosis compared to either cytokine alone (208, 209, 218). 
The importance of multifunctional T cells in immune reactions against tuberculosis (219), in 
BCG-vaccinated infants (220) and people who live in high infected areas (221) has been 
studied before. Multifunctional, high-level cytokine-producing Th1 cells in the lungs of mice 
have been associated with enhanced protection against M. tuberculosis (208, 210, 222). There 
is some evidence that protection against pathogens such as Leishmania major is associated 
with multifunctional T cells making IL-2, IFN and TNF (181). The induction of 
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multifunctional T-cells is a new approach in to the process of vaccine development (223, 
224). We speculate that a high frequency of mKatG specific multifunctional T cells with a 
high per cell cytokine content may help clearance of the assumptive pathogenic antigen in 
sarcoidosis patients with Löfgren´s syndrome. Probably the potency of multifunctional T 
cells is due both to their double cytokine production, and the higher per cell cytokine content 
of each cytokine 
As we described before sarcoidosis patients who are HLA-DR3+ most commonly have 
Löfgren´s syndrome and a good prognosis. The accumulation of AV2S3+ T cells in the lungs 
(>10.5% of total CD4
+
 T cells) is an interesting characteristic of the patients in this group. 
TCR AV2S3
+
 T cell proliferation of PBMC from healthy DR3+ BCG vaccinated individuals 
following in vitro stimulation with Mycobacterium tuberculosis extract has been shown by 
our group before (225). Our group in collaboration with John Hopkins University has 
reported a correlation between the frequency of BAL TCR AV2S3+ T cells and BAL IFNγ 
producing cells in response to mKatG by Elispot (120). In the current study we show, for the 
first time, the capability of BAL TCR AV2S3+ T cells to react against mKatG. 
Our data demonstrated that TCR AV2S3+ T cells responded with IFNγ production to a 
significantly higher extent than the TCR AV2S3-
 
T cells (median 0.65% vs. 0.48%, p=0.016). 
This finding indicates that mKatG could be a specific disease-related antigen that is capable 
to trigger different subsets of T cells. It is important to remember that mKatG is a large 
protein, approximately 700 amino acids, and likely contains several T cell epitopes that can 
be recognized by various TCRs. It is therefore not surprising that both TCR AV2S3+ and 
AV2S3- T cells can respond to the same protein.   
Similar to our findings in BAL, the blood TCR AV2S3+ T cells also responded to mKatG to 
a higher extent than blood TCR AV2S3- T cells. We speculate that the TCR AV2S3+ T cells 
are re-circulating throughout the body. The alveolar T lymphocytes can reach regional lymph 
nodes by leaving the alveoli through the alveolar epithelium. Via the regional lymph nodes 
they can be distributed all over the body to rejoin the systemic immune system (226). 
Alternatively, the sarcoidosis antigen that stimulates the TCR AV2S3+ T cells may be 
distributed systemically. 
Our group has previously shown that the frequency of CD4+ AV2S3+ T cells in BAL of 
patients after clinical recovery is normalized (180).  This indicates that the number of BAL 
TCR AV2S3+ T cells correlates with disease activity. Furthermore we know that there is an 
association between the number of CD4+ AV2S3+ T cells and good prognosis (227). 
Previously, our group also reported that expression of activation markers such as CD26, 
CD28, CD69, and HLA-DR were enhanced in AV2S3+ BAL CD4 T cells compared to 
AV2S3- subsets. These data suggested that AV2S3+ CD4+ T cells in the lung  are 
significantly more activated and differentiated compared to AV2S3- CD4+ lung T cells (228, 
229).  Moreover, in another study we showed a sharply reduced expression of the regulatory 
T cell transcription factor Foxp3 in BAL AV2S3+ CD4+ T cells of DR3+ sarcoidosis patients 
compared to AV2S3- cells (230) This indicates that BAL AV2S3+ CD4+ T cells are effector 
cells rather than regulatory T cells. These findings together with our observation of Th1 
cytokine production by these cells and a higher response of TCR AV2S3+ T cells to mKatG 
compared to the other CD4+ T cells suggests that TCR AV2S3+ T cells are associated with 
good prognosis and spontaneously resolving disease because of their ability to secrete 
effector cytokines upon mycobacterial antigen stimulation, possibly leading to antigen 
elimination. 
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The TCR AV2S3+ T cell subset is not a T cell clone but it constitutes an oligoclonal T cell 
subset. The variable (V)  chain can associate with different Vβ chains. Most recently our 
group identified 16 different Vβ CD4+ T cell expansions in BAL of sarcoidosis patients and a 
preference of TCR AV2S3+ T cells to pair with Vβ22, Vβ7 and Vβ18 has been shown before 
using PCR (146, 231). We also have data based on flow cytometric analysis that indicates a 
preference for V2.3 to pair with V22, although not in a majority of Va2.3+ cells (Kaiser et 
al, unpublished observations). T cell clones can exhibit different avidity towards a given 
antigen; one study showed that some clones only proliferated, whereas others both 
proliferated and produced cytokines, in response to a given concentration of the same antigen 
(232). 
BAL T cells preferentially exhibited a CD27- phenotype while in blood the majority of CD4+ 
T cells were CD27+ T cells. Our findings thus revealed that differentiated T cells localized in 
inflamed organ. BAL CD27- T cells produced more IFNγ in response to mKatG, while in 
blood the CD27+ T cells were the major cytokine producing cells. Similarly in chronic 
beryllium disease (CBD), i.e. a granulomatous disease like sarcoidosis, characterized by 
infiltration of beryllium-specific CD4+ T cells in the lungs, the majority of cytokine 
producing T cells are CD27- (233). CD27, a co-stimulatory molecule (member of the 
TNF/NGF-R family), is expressed on the naïve and memory T cells. Activation of T cells via 
TCR/CD3 induces high CD27 surface expression. However, following prolonged activation, 
CD27 becomes gradually switched off (234-236). Our findings are therefore compatible with 
long-term antigen stimulation in the lungs. 
 
4.2 IL-17 and antigen-specific IL-17-responses in sarcoidosis (Paper II) 
T helper 17 is a subset of CD4+ T helper cells that less than a decade ago was identified as a 
distinct T cell lineage (237) and production of interleukin IL-17 (synonymous to IL-17A), a 
pleiotropic cytokine with widespread effects, is the hallmark of this subset of T cells (26). IL-
17 is an essential player in host defense in several mammalian organs including the lungs of 
humans (182, 238). Th17 cells were recognized as a key factor in protection against 
extracellular bacterial and fungal pathogens like Klebsiella pneumoniae (239), Citrobacter 
rodentium and Candida albicans (240), while other studies showed the role of Th17 cells in 
protection against intracellular bacteria like Mycobacterium tuberculosis and Salmonella 
enterica (241). An impaired function of IL-17 results in increased bacterial burden and 
reduced overall host survival (242). IL-17 and IL-17-producing cells are thought to play a key 
role in chronic inflammation like mycobacterial infection, rheumatoid arthritis and other 
autoimmune disorders and also granuloma formation (243-245). Involvement of Th17 and Il-
17 producing cells in inflammatory lung disorders such as asthma, COPD and ILDs have also 
been reported in several studies. Up-regulation of IL-17 has been reported in patients with 
asthma (246), although the exact role of IL-17 in asthmatic responses is difficult to define. It 
can be speculated that IL-17 in asthma doesn’t have a prominent role and the influence of IL-
17 in pulmonary inflammation is mostly restricted to neutrophil dependent disorders or Th2 
independent chronic inflammation (247). 
The involvement of IL-17 and IL-17-producing T cells in sarcoidosis has been reported by 
different groups, although there is some discrepancy regarding the role of IL-17 in 
pathogenicity of sarcoidosis. Facco et al. detected persistence of Th17 cells in both BAL and 
blood of sarcoidosis patients. They could also detect IL-17 producing cells surrounding the 
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central core of the granuloma from sarcoidosis patients. They also reported trafficking of 
Th17 cells to the lungs of sarcoidosis patients mediated by CCL29 (CCR6 ligand) (125). An 
increased population of Th17 cells in blood of sarcoidosis patients has been reported by Ten 
Berge et al. (126). They have also shown an increased proportion of IL-17/IFNγ double 
producing cells in BAL and blood of patients and increased numbers of IL-17 producing cells 
in and around granulomas. A significant correlation between IL-17 and IL-6 levels was 
detected by Urbankowski et al. in BAL of sarcoidosis patients (248). In contrast to Ten 
Berge, Furusawa et al. reported a decline in IL-17 mRNA level in PBMCs from patients with 
sarcoidosis compared to controls and they didn’t observed any response to ESAT-6 
stimulation (mycobacterial antigen) (249). Wonder Drake’s group showed a greater number 
of Th17 cells in BAL and blood of sarcoidosis patients versus controls. In a sharp contrast 
with Furasawa’s findings, they demonstrated an increase in ESAT-6 specific Th17 cell 
responses in BAL and blood of sarcoidosis patients compared to controls. Moreover they 
reported a reduction in expression of IFNγ by Th17 cells in sarcoidosis patients (250). 
Tondell et al. finally reported a lower fraction of Th17 cells in sarcoidosis patients compared 
to controls. However, they found a higher proportion of IFNγ producing Th17 cells in 
sarcoidosis patients and this was correlated with radiologic stage (251). 
Our data reveals the presence of T cells making IFNγ as well as IL-17 in response to the 
mycobacterial antigen mKatG in sarcoidosis patients. mKatG-reactive IL-17 producing cells 
were found in the affected organ, the lung, as well as in peripheral blood. We and others 
previously showed the presence of mKatG-reactive IFNγ producing effector T cells in 
sarcoidosis patients (120). We have also reported a more pronounced IFNγ production by 
CD4+ TCR AV2S3+ T cells compared to CD4+ TCR AV2S3- T cells in response to mKatG 
(252). Altogether these findings indicated mKatG behaves in a manner expected for a 
pathogenic antigen. 
Here for the first time, we have shown mKatG-specific IL-17 responses in BAL of 
sarcoidosis patients with higher frequency of mKatG-reactive IL-17 producing cells in BAL 
of sarcoidosis patients with Löfgren’s syndrome compared to patients without Löfgren’s 
syndrome (Figure 5a). Furthermore sarcoidosis patients with Löfgren´s syndrome and more 
precisely sarcoidosis patients with Löfgren´s syndrome who are DR3+ (patients with 
accumulation of CD4+ TCR AV2S3+ T cells in the lungs) had higher levels of IL-17 in 
BALF (Figure 5b). Importantly this pioneer finding could be a validation for the pathogenic 
role of mKatG in a subset of sarcoidosis patients. The specific capacity of the HLA-DR3 
molecule in presenting sarcoidosis-specific antigen(s) such as mKatG for T cells followed by 
induction of Th17 cells in the lungs of DR3+ sarcoidosis patients with Löfgren’s syndrome 
can be a possible explanation for higher levels of soluble IL-17 in this subset of patients. 
Our findings demonstrated that mKatG-reactive IFNγ producing cells are dominant compared 
to mKatG-reactive IL-17 producing cells in BAL of sarcoidosis patients. However, given the 
importance of Th17 and IL-17 producing cells in the immunopathogenesis of several 
inflammatory and autoimmune diseases (253), we propose that the observed Th17 responses 
against the mycobacterial protein mKatG could contribute to the inflammation in sarcoidosis. 
The accumulation of IL-17 producing cells reactive to mKatG in the lungs of sarcoidosis 
patients may be a result of trafficking or local proliferation of antigen-specific IL-17 
producing cells at the site of granulomatous inflammation. 
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The finding of more IL-17-producing cells responding to mKatG in sarcoidosis patients with 
Löfgren´s syndrome locally at the site of inflammation suggests further qualitative 
differences in the mKatG-specific responses between patients with and without Löfgren´s 
syndrome. Due to the very good prognosis in DR3+ sarcoidosis patients with Löfgren’s 
syndrome we postulate that IL-17-producing cells play a role in the presumed elimination of 
antigen and spontaneous recovery that is characteristic for DR3+ patients with Löfgren´s 
syndrome. 
 
Figure 5: mKatG-specific IL-17 responses and IL-17 levels in patients with 
pulmonary sarcoidosis. (a) Elispot assay for evaluation of mKatG specific IL-17 
producing cells in BAL of patients with and without Löfgren´s syndrome. (b) IL-
17 levels in BAL fluid determined by Immuno-PCR and compared in healthy 
controls, sarcoidosis patients without Löfgren’s syndrome and with Löfgren’s 
syndrome. Sarcoidosis patients with Löfgren´s syndrome were divided into two 
groups (HLA-DR3+ and HLA-DR3-). 
Both Th1 and Th17 cells are required and interact in different steps for host defence against 
mycobacterial infection. In the lungs of vaccinated animals after M. tuberculosis challenge, 
expression of the CXCR3 ligands i.e. CXCL9, CXCL10 and CXCL11 have been induced by 
IL-17, thereby IL-17 can regulate trafficking of Th1 cells to the site of infection (241). IFNγ 
and IL-17 T cell responses to M. tuberculosis antigens are time dependent and IL-17 
producing T cells accumulate in the lungs more rapidly than IFNγ-producing T cells; 
furthermore IFNγ and IL-17 may act in synergy to initiate inflammation (254). IL-17 
stimulates the activity of the transcription factor NF-κB (255); activation of NF-κB in antigen 
presenting cells in turn affects Th1 responses and leads to development of IFNγ producing T-
cells (256). IL-17 is not only involved in neutrophil-mediated inflammatory responses, but 
also it is an important cytokine in the induction of an optimal Th1 response and protective 
immunity against mycobacterial infection. We speculated that the higher expression of IL-17 
and mKatG specific IL-17-producing cells in sarcoidosis patients with Löfgren’s syndrome 
help to induce Th1 responses, and contribute to a more rapid and diverse effector T cell 
response, which then contributes to the protection against unknown antigen(s). 
The inflammatory properties of IL-17 and IL-17 producing cells are irrefutable and 
involvement of IL-17 in the pathogenesis of several inflammatory disorders, in particular 
autoimmune diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), psoriasis 
and inflammatory bowel disease (IBD) has been reported before (19, 257). IL-17 has been 
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considered as a potent pro-inflammatory cytokine that induces expression of different 
inflammatory mediators such as IL-6, TNF-α, IL-1β, GM-CSF, CXCL1, CXCL8, CCL2, 
CCL7 and CCL20 by different cell types like epithelial cells, endothelial cells and 
macrophages (258). Th17 and possibly other IL-17 producing cells in sarcoidosis patients can 
be considered as potent mediators of inflammatory responses because of their ability to 
induce trafficking and activation of inflammatory innate immune cells at the site of 
inflammation (259, 260). 
More recently there is some evidence for an immune-modulatory or non-pathogenic role for 
IL-17. The role of IL-17 and antigen specific IL-17 producing cells in the pathogenesis of 
experimental autoimmune uveitis (EAU) has been demonstrated before (261). Yan Ke et al., 
however, identified an anti-inflammatory role for IL-17 in the EAU model. They found that 
in EAU-susceptible rats, treatment with small doses of IL-17, rather than exacerbating the 
clinical score of the disease, lead to suppression of EAU development and unexpectedly 
ameliorated the clinical score of EAU. They thus concluded that IL-17 has both pro- and anti- 
inflammatory effects on the development of EAU (262). O’Connor et al have demonstrated a 
protective function for IL-17 in a mouse IBD model and suggested that this function is 
exerted partly by suppressing Th1 differentiation. They also showed that absence of IL-17 led 
to an accelerated and severe disease accompanied by higher expression of genes encoding 
Th1 type cytokines (263). Thus, we cannot exclude this type of beneficial effect of IL-17, 
particularly in the DR3+ Löfgren´s patients.  
Another recent and intriguing finding is that Th17 cells can be polarized to become 
pathogenic or non-pathogenic depending on the environmental cytokines or mediators (22). 
Kuchroo’s group has shown a critical role of TGF-β in development of Th17 cells. They 
reported that although the presence of IL-23 has been considered to be essential for 
developing the pathogenic Th17 phenotype, TGF-β3 can differentiate naïve T cells into 
pathogenic Th17 cells without any need for further exposure to IL-23. In fact both TGF-β1 
and TGF-β3 are able to induce Th17 cells, but Th17 cells induced by TGF-β1 are not 
pathogenic whereas TGF-β3 has an important role in induction of pathogenic and pro-
inflammatory Th17 cells. We know from previous studies that the levels of some cytokines 
like TGF-β1 that may influence differentiation of Th17 cells, differ between sarcoidosis 
patients with or without Löfgren’s syndrome (211). 
Our findings indicate that in sarcoidosis patients, there is a subset of T cells which has the 
ability to produce both IFNγ and IL-17 simultaneously. In fact, we found that a majority of T 
helper 17 cells can also produce IFNγ. Existence of these hybrid T cells has been reported 
before in other inflammatory diseases and also sarcoidosis (126). Monteleone et al. 
demonstrated that as a consequence of cytokines and microenvironmental molecules in gut 
mucosa of IBD patients, conditions are generated that result in that some IFNγ producing 
cells originate from previously IL-17 producing T cells (264). Conversion or switching of T 
helper cells from IL-17 producing to IFNγ producing cells is a phenomenon that is dependent 
on the cytokine environment. IL-1, IL-6 and TGF-β have important roles in the cytokine 
signature of Th17 and IL-17 producing cells. TGF-β is essential for sustained expression of 
IL-17A by Th17 cells. In the absence of TGF-β, both IL-23 and IL-12 cause suppression of 
IL-17 expression and instead enhance IFNγ production (265). Importantly, there is evidence 
that hybrid Th1/Th17 T cells are more pathogenic than conventional Th17 cells (266). CD4+ 
AV2S3+ T-cells and CD4+ AV2S3- T-cells displayed differences with regard to the capacity 
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to express IFNγ and IL-17. However, further studies are needed to investigate the frequencies 
of such hybrid T cells in patient subgroups versus healthy control subjects. 
In most cases the first option for reducing the inflammation in sarcoidosis patients is to 
prescribe corticosteroids. In recent years, the blocking and controlling of IL-17 and IL-17 
producing cells is one of the strategies that have been used for treatment of inflammatory 
disorders, for instance administration of antibody against IL-17 described in RA and psoriasis 
(267, 268). On the other hand, a protective effect of IL-17A in inflammatory bowel diseases 
(IBD) and uveitis has been reported before (24, 262). Given our findings that indicated higher 
level of IL-17 and increased IL-17 responses among a subgroup of sarcoidosis patients with 
good prognosis, it remains to be elucidated whether inhibiting this signaling will offer clinical 
benefits for patients. Therefore, a more detailed understanding about the pathogenic or 
protective role of Th17 cells in various subsets of sarcoidosis patients is needed. 
 
4.3 Characteristics of effector and regulatory T cell subsets in the lungs of 
smoking and non-smoking healthy individuals (Paper III) 
Cigarette smoke intrinsically induces local inflammation; however, it is associated with both 
release and inhibition of pro-inflammatory and anti-inflammatory mediators that influence 
different T cell subsets. T helper lymphocytes have a pivotal role in orchestrating the host 
defense and inflammatory reaction following triggering by specific antigens. Our group has 
demonstrated an impact of smoking on the distribution of BAL T cell subsets in the context 
of COPD studies (269). In the present study, in order to better understand the influence of 
cigarette smoking on T cells in relation to the pathogenesis of smoking-induced diseases, we 
investigated frequencies and characteristics of lung and blood CD4+T cell subsets such as T 
helper 1 (Th1), Th17 and Treg cells (and corresponding subsets in CD8+ T cells) in 18 
healthy young and moderate smokers and 15 never-smoking individuals. 
Our findings indicated a lower CD4/CD8 ratio of BAL T cells in healthy smokers. A higher 
rate of apoptosis in alveolar cells and alterations in glycoproteins in smokers can be possible 
explanations for changing this ratio in BAL and blood. Cigarette smoke components and even 
the gaseous phase can directly induce both apoptosis and necrosis of lymphocytes at the site 
of exposure (270, 271). 
Our data demonstrated that healthy smokers had a lower frequency of BAL CD4+ IL-17 
producing cells compared to healthy never smokers. Inflammatory responses can be induced 
by smoking and involvement of IL-17 producing cells in this has been reported before (158, 
245). A higher frequency of IL-17 producing cells in the bronchial biopsies of COPD patients 
compared to control non-smokers has been documented. Although COPD patients are 
different from healthy smokers with normal lung function, studies on the role of IL-17 in 
COPD patients can be informative.  
COPD is an enhanced chronic inflammatory response in the airways and the lung to noxious 
particles or gases in particularly cigarette smoke and is characterized by persistent and 
progressive airflow limitation (272). Increased production of IL-17A in the bronchial 
submucosa and infiltrating inflammatory cells in small airways has been reported (273, 274). 
Chang et al. reported expression of IL-17A by both CD4 and CD8 T cells in the lung 
submucosa from COPD patients and suggested that IL-17 producing cells play an important 
role in the pathogenesis of COPD by inducing an accumulation of neutrophils in the lungs of 
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COPD patients (275). Airway epithelial cells were induced by IL-17 to produce mucus and 
matrix metalloproteinase-9 (MMP-9) and dysregulation of MMPs contribute to the 
destruction of lung tissue in COPD (276). Neutrophils can contribute in the pathogenesis of 
COPD by secretion of proteolytic enzymes such as neutrophil elastase (277). Elastin is a 
major constituent of the extracellular matrix in the lungs and it can be degraded by neutrophil 
elastase, leading to mucus hyper-secretion (278). Moreover it has been suggested that elastin 
can act as an auto-antigen in the lung of COPD patients by inducing of Th1 and Th17 cells 
against elastin (276). It has been suggested that in COPD patients with frequent exacerbations 
and excessive mucus production, these phenomena can be attributed to IL-17 mediated 
neutrophilia (245). Shen et al. has demonstrated not only that the concentration of IL-17 and 
neutrophil percentage decline in the lungs of tobacco-smoke-exposed mice which were 
treated with anti-IL-17 antibodies, but also the pathological score of small airway 
inflammation was improved (279). This indicated the importance of IL-17 in the 
pathogenesis of COPD. Doe et al. demonstrated a similarity in IL-17 expression between 
COPD patients and healthy smokers but no association with increased neutrophilic 
inflammation (280). 
There is no consensus on the effect of smoking on IL-17 producing cells in healthy smokers 
with normal lung function and this is partly related to variations in methodology and 
differences regarding the characteristics of studied populations. Tobacco smoking can induce 
an antigen specific Th17 response in certain individuals (281) and higher relative expression 
of IL-17 mRNA in lung tissue of smokers has been reported before (282). Our finding 
regarding the frequency of BAL CD4+ Th17 cells are in contrast with these studies. We 
found a reduced IL-17 expression by BAL CD4+ T cells of light smokers but an increase in 
the number of cigarettes per day caused an increased IL-17 expression. We should emphasize 
that most studies related to the effect of smoking on T cells focused on differences between 
never-smokers and smokers who were matched with COPD patients with regard to smoking 
history, while the present study was performed on samples from mild smokers. 
The frequency of IFNγ-producing CD8 T-cells increased in BAL of healthy smokers after 
anti-CD3/CD28 stimulation and this increase was more intensive in heavy smokers. Freeman 
et al. demonstrated increased production of inflammatory cytokines by CD8+ T cells in 
COPD patients.The lung CD8+ T cells respond to danger signals by up-regulating 
inflammatory mediators and cytotoxic molecules (283, 284). IFN-γ is a key cytokine in the 
development of the airway obstruction and pulmonary destruction in COPD by induction of 
different mediators (285). 
Bacterial burden and susceptibility to develop some infections increase among smokers 
(286). Cigarette smoke exposure can inhibit T cell responses to M. tuberculosis and influenza 
virus in a mouse model (287). Lugade et al. demonstrated a negative effect of cigarette smoke 
exposure on the generation of adaptive immune responses to nontypeable Haemophilus 
influenzae (NTHI) (288). Although in contrast to our findings they reported increased IL-17 
response and decreased IFNγ response to NTHI chronic infection in mice with chronic 
cigarette smoke exposure. There may however be several reasons for this discrepancy, such 
as species differences, the level of smoke exposure, infection in mice versus in vitro 
stimulation of human T cells with anti-CD3 antibodies. Due to the important role of Th17 
cells in host defense against bacterial or viral infections, we propose that the decline in 
expression of IL-17 in smokers can increase infection susceptibility. 
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The multifunctional T cells (cells that produce two or more cytokines simultaneously) as well 
as hybrid cells (T-cells which are capable to produce cytokines from two different T cell 
lineages) have been studied in BAL and blood of healthy smokers and non-smokers. The 
multifunctional IFNγ/TNF producing cells are associated with either a protective role or are 
indicative of active disease in tuberculosis (289-291). IFNγ/IL-17 producing T cells is an 
example of hybrid T cells and indicates plasticity between Th1 and Th17 cells. Less is known 
about the function of these hybrid T cells but there is some evidence to suggest that Th17/Th1 
T cells are more pathogenic than conventional Th1 or Th17 cells in the context of 
autoimmunity (266, 292). We believe these multifunctional or hybrid cells are potent 
functional T cells which play an important role in host defense. Our findings demonstrated a 
decline in BAL CD4+ IFNγ/IL-17 and IL-17/TNF producing cells in healthy smokers 
compared to never smokers. The reduction of these potent T cells could negatively impact on 
the capacity of the immune system in smokers to control pulmonary infections. 
Our findings on regulatory T cells (Treg) showed no difference in the proportion of Foxp3+ 
CD4+ T cells in BAL of smokers and never-smokers. Similarly to the situation for IL-17, 
there is no consensus on the impact of smoking on Treg cells and an augmented or abated 
frequency of FoxP3 expression (293, 294) and even variation between smokers and non-
smokers in different compartments of lung tissue has been reported. Isajevs et al. have 
demonstrated increased Foxp3 expression in large airways of smokers and COPD patients but 
a decreased percentage of Foxp3+ cells in small airways of COPD patients (295). 
Furthermore, we found that Foxp3+ CD4+ regulatory T cells in BAL of smokers did not 
show any IL-10 production (Figure 6a). IL-10 is a suppressive cytokine that hinders 
transcription of many genes which are normally induced via pattern recognition receptors.  
Many immune cell types including effector or regulatory T-cells can produce IL-10 (296). 
IL-10 can be produced by Foxp3+ Treg cells in tissues such as colon or lungs and it is needed 
for restraining immunological hyperreactivity at these interfaces with the environment, but is 
not needed to control systemic autoimmunity (297). We speculate that the lack of IL-10 
production by Foxp3+ CD4+ regulatory T cells in BAL of smokers may reflect a defective 
function of regulatory T-cells which is caused by cigarette smoke components. Roos-
Engstrand et al. have shown that despite similar frequencies of T cells expressing Foxp3 in 
smokers and non-smokers, the numbers of non-functional Tregs with a CD4+ CD25+ 
phenotype that do not express Foxp3 is higher in healthy smokers compared to non-smokers 
(298). 
Tregs constitute a heterogeneous population with diverse sub-populations, e.g. thymus-
derived Tregs (tTregs), and peripherally derived Tregs (pTregs). These Treg variants have 
different functions and it has been proposed that tTregs modulate T-effector cell trafficking, 
while pTregs inhibit T-effector priming (37, 44). Helios is a member of the Ikaros 
transcription factor family and recently has been considered as a marker of natural or thymic-
derived Treg cells (38), although this has later been challenged (39) and more recently, 
Helios has been suggested to be a marker of anergic effector cells or a T cell activation and 
proliferation marker (40, 41). Regardless of Helios qualification as a tTreg or activation 
marker our findings indicate a remarkable increase in the proportion of Helios- Foxp3+ Tregs 
in healthy smokers (Figure 6b). Raffin et al. found that Helios
−
 Tregs, but not Helios
+
 Tregs 
has capacity to secrete IL-17 and IL-10 (299). In agreement with their findings, our data 
indicated that expression of IL-10 and IFNγ in Foxp3+ Tregs was almost exclusively 
confined to the Helios- subset. Moreover we found that the fraction of IL-10 positive cells in 
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the Helios- Tregs was significantly reduced in smokers (Figure 6c) and no such difference 
was observed for IFNγ production. The lower expression of IL-10, but not IFNγ, in 
Foxp3+Helios- BAL Tregs of smokers may indicate that smoking induces a defective 
function in Foxp3+Helios- Tregs. Alternatively, if Helios- Treg cells remain potent 
suppressors, the observed decrease in Th17 cells and other inflammatory cytokine producing 
cells in smokers may be partly ascribed to a high frequency of these Helios- Tregs in 
smokers. Such a scenario would be in accordance with Raffin’s finding that demonstrated 
Helios- Tregs have higher suppressive capacity versus to Helios+ Tregs (299). Our finding of 
a reduced ratio of IL-17- to IL-10-producing CD4+ BAL T cells in healthy smokers is in 
contrast to the findings in smoke-exposed mice by Wang, although their model was based on 
heavy smoke exposure that induced a COPD-like disease (300). 
 
 
Figure 6: Analysis of regulatory T cells, (a) comparison of the frequency of BAL 
CD4+ Foxp3+ T cells that produce IL-10 between smokers and non-smokers. (b) 
Comparison of fractions of BAL CD4+ Foxp3+ T cells that are Helios- in 
smokers and non-smokers. (c) Comparison of IL-10 production by 
Foxp3+Helios- BAL CD4+ T cells between smokers and non-smokers. 
 
There are discrepancies between different studies as to the effect of smoking on T-cell 
responses and several explanations are plausible. Daily quantity of exposure, smoking 
history, intensity of smoking inhalation varies between different smokers and those are just 
some of the factors that have an influence on T-cell function studies. Genetic background and 
socioeconomic status are other factors that contribute to the results. Whether studies were 
performed on human or mouse samples, and design of study ex vivo or in vitro as well as the 
choice of experimental techniques are other factors that affect the T-cell responses observed.  
In conclusion, our findings implied that a change in subset composition of Tregs and reduced 
IL-10 production by Tregs may be of importance for induction of smoking-induced diseases 
such as COPD and autoimmune disorders. 
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4.4 Characteristics of lung T cell subsets in multiple sclerosis patients    
(Paper IV) 
Cigarette smoke is recognized as a major risk factor for developing several diseases. In 
addition to the lung related disorders smoking has also been associated with risk of disease or 
to disease phenotype in a number of important autoimmune disorders (151, 301). 
Rheumatoid arthritis (RA) is one of the immune mediated diseases with a striking example of 
gene-environment interaction. Certain variants of HLA–DRB1*01 and HLA–DRB1*04 are 
called the shared epitope genotype. A study on RA patients demonstrated a gene-environment 
interaction as the combination of smoking history and having two copies of HLA-DR “shared 
epitope” genes increased 21-fold the risk of the RA in the subgroup of patients who are 
positive for antibodies to citrullinated protein antigen (ACPA) (162, 302). Part of the 
mechanism appears to be that cigarette smoke induces the PAD enzymes responsible for 
citrullination (a post-translational modification) of proteins such as vimentin (163). 
MS is another example of autoimmune disease where cigarette smoking strongly increases 
the risk of developing MS in people with genetic susceptibility, in this case carriage of HLA-
DRB1*15 and absence of HLA-A*02 (171). Furthermore Odoardi et al. by study on Lewis 
rat transfer experimental autoimmune encephalomyelitis (EAE, a model of MS) have recently 
demonstrated that the lungs can contribute to the activation of potentially autoaggressive T 
cells and their transition to a migratory mode as a prerequisite to entering their target tissues 
and inducing autoimmune disease (303) and they concluded that T cells become educated in 
the lung to enter to the central nervous system. 
T cells play an important role in orchestrating inflammation. However, very little is known 
about how smoking may lead to autoimmunity. To better understand the mechanisms behind 
the T cell activation in the lungs we investigated frequencies and characteristics of lung and 
blood CD4+ and CD8+ T cell subsets in seventeen MS patients (8 smokers and 9 non-
smokers) (10 treated with IFNβ, 3 with natalizumab and 4 untreated patients) and twenty 
three healthy individuals (14 smokers and 9 non-smokers). IFNβ and natalizumab are two 
common, and the most effective, treatments in MS patients. 
Pulmonary complications are reported in some MS patients, caused by pulmonary muscle 
dysfunction and destruction of cranial nerves (304). We didn’t find any pulmonary 
complications in our patients and all enrolled patients had normal lung function.  
Increased level of inflammatory cytokines such as IFNγ and IL-17 in CNS and blood from 
MS patients has been well documented (305-307). A dominant response of either Th17 or 
Th1 type has been reported to be associated with differences in preferential involvement of 
brain or spinal cord respectively and disease phenotype (166, 308). Our findings regarding 
BAL T cell cytokine production demonstrated that IL-17 production in BAL CD4+ T cells 
declines in MS patients regardless of smoking status and this effect is probably related to the 
treatment. The suppression of IL-17 production by IFNβ has been reported before and it has 
been suggested that this effect is exerted via induction of IL-27 secretion by dendritic cells 
(309, 310). 
Sweeney et al. reported a correlation between reduced frequency of Tregs and severity of 
clinical symptoms of MS patients (310). Moreover, there are some studies that show 
defective suppressive function of Tregs in MS patients (43). Treatment with IFNβ leads to 
up-regulation of GITRL on dendritic cells and down-regulation of CTLA-4 on Tregs. CTLA-
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4 induces negative signal into T cells to inhibit T cell proliferation, while GITR delivers 
costimulatory signals to induce T cell proliferation. Thus up-regulation of GITRL on 
dendritic cells and down-regulation of CTLA-4 on Foxp3+ T cells could provide a signal to 
motivate proliferation of regulatory T cells. It has been shown that there is an increased 
frequency of Foxp3+ Tregs and a partial improvement of Treg suppressive function in MS 
patients treated with IFNβ (311, 312). In accordance with other studies, we detected no 
significant difference in the frequency of Foxp3+ CD4+ T cells in BAL and blood of MS 
patients compared to controls (313). However, IFNβ treated patients have the highest 
frequency of Foxp3+ cells among our patients. We believe that the similarity in frequency of 
Foxp3+ T cells between patients and controls is likely related to the effect of IFNβ treatment. 
We propose that an increased frequency of BAL Foxp3+ T cells in both natalizumab and 
IFNβ treated patients and decrease in IFNγ and IL-17 producing cells in BAL of treated 
patients might indicate that treatment with IFNβ or natalizumab restored the frequency and 
function of Foxp3 regulatory T cells in BAL of patients, but the reason for this effect to occur 
in the lung and not in peripheral blood remains to be addressed.  
Foxp3 instability and Treg plasticity is another reason for impaired function of Tregs. 
Komatsu et al. demonstrated conversion of Foxp3+ Tregs into Th17 cells leading to increased 
numbers of pathogenic Th17 cells in arthritis and IL-17 producing exFoxp3 cells have 
pathogenic function with higher affinity to self-antigens (314). Dominguez et al. reported 
higher frequency of IFNγ producing Foxp3+ T cells, i.e. Th1-like Tregs, in untreated MS 
patients. These Th1-like Tregs are regulatory T cells affected by functional plasticity with 
reduced suppressive function (315) and after treatment with β-interferon, their frequency 
were normalized in MS patients. In accordance with findings of Dominguez, we did not 
detect any differences in BAL Th1-like Tregs between MS patients and healthy controls since 
the most of enrolled patients were treated. However, we found that these plastic Tregs in 
BAL were affected by environmental signals since the frequency of Th1-like Tregs declined 
in both healthy smokers and MS smokers compared to non-smoking individuals.  
IL-10 is a regulatory cytokine expressed by numerous cell types. It is a potent anti-
inflammatory cytokine, which through its suppressive effects on many cells inhibits various 
inflammatory pathologies (316). IL-10-producing CD4+CD25+ T cells are present mainly 
within the intestinal lamina propria and resolution of murine colitis is dependent on the 
presence and enrichment of IL-10-producing CD4+CD25+ T cells in the intestine (317). 
Ranatunga et al. described that colitis resistance is associated with accumulation of IL-10 
producing Foxp3+ T cells within the lamina propria. They also reported that IL-10 producing 
cells control expression of inflammatory cytokines and reduce the accumulation of 
pathogenic Th17 cells in the gastrointestinal tract (318). IL-10 has also been found to be of 
importance for immune regulation at the epithelial surfaces in the lungs. It has been reported 
that lung CD4+CD25+Foxp3+ T cells from naive mice can reduce airway hyper-
responsiveness by a mechanism dependent on the induction of both IL-10 and TGF-β 
production (319, 320). Our findings demonstrated a down-regulation of IL-10 production by 
Foxp3+ Tregs in BAL of both healthy smokers and MS patients (regardless of smoking 
status). Thus, smoking-induced impairment of Treg function may be one factor that promotes 
autoimmunity, but several other mechanisms likely can contribute to such immune 
dysregulation. It remains to elucidate the exact role of IL-10 producing CD4+ Foxp3+ 
regulatory T cells in MS patients. 
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Regulatory T cells play a critical role in immune homeostasis and Foxp3 is considered as a 
master transcription factor in the development of Tregs. Tregs can be categorized into two 
main subgroups: natural regulatory T cells (tTreg) and adaptive regulatory T cells (pTreg) 
(321). tTregs that develop in the thymus and their main responsibility is to prevent 
autoimmunity in response to self-antigens, whereas pTregs are generated in the periphery in 
response to antigen stimulation and their function is to control and suppress T cell activity 
against foreign or neo-antigens (322). Helios is another transcription factor that plays an 
important role in the function of regulatory T cells. Raffin et al demonstrated that Helios- 
Tregs are potent regulatory T cells with higher suppressive capacity (299). They suggested 
Helios can be a marker of tTregs, although the validity of this is controversial, and 
alternatively Helios has been considered as an activation marker. They have shown that 
Foxp3+/Helios- Tregs have capacity to secrete IL-17 and IL-10. Moreover, these cells lose 
suppressive function under specific circumstances and switch to a pro-inflammatory 
phenotype. Our study demonstrated an increase in the frequency of Foxp3+Helios- Tregs and 
a corresponding decrease in Foxp3+Helios+ Tregs in BAL of MS patients. Thus we could 
detect in the BAL of MS patients a down-regulation of a Treg subset which is associated with 
control on self-reactive T cells and with a stable suppressive phenotype. Moreover we found 
an increase in the frequency of Foxp3+Helios+ Tregs in IFNβ treated patients that might be 
one of the main benefits of IFNβ treatment. 
Finally, the balance between Treg and Th17 cell subsets plays an important role in the 
development of autoimmune and inflammatory diseases (323). A high frequency of IL-17 
producing CD4+ T cells (307) and low frequency of Foxp3+ T cells have been reported in 
MS patients with active disease (324). In contrast, we found an increase in the ratio of 
Foxp3/IL-17 cells in both BAL and blood of non-smoking MS patients compared to healthy 
controls and this ratio was elevated in patients who treated with β-interferon. The 
Foxp3/Th17 ratio was increased in patients treated with β-interferon, mainly because the 
treatment caused an increased frequency of Foxp3+ T cells. However, we believe that the 
notion of a Treg/Th17 imbalance may be too simplistic to explain important features of the 
immunopathogenesis of MS, and the characteristics of Th17 and Treg cells need to be 
considered separately. 
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5 CONCLUSIONS 
 
 There was a higher frequency of mKatG reactive IFNγ  producing CD4+ T cells 
within the AV2S3+ subset compared to AV2S3- cells of both BAL and blood from 
HLA-DR3+ sarcoidosis patients with Löfgren’s syndrome and a lung accumulation of 
TCR AV2S3+ CD4+ T cells. 
 
 Sarcoidosis patients with Löfgren’s syndrome had higher proportions of 
multifunctional cytokine producing T cells (IFNγ /TNF) in response to mKatG 
compared to patients without Löfgren’s syndrome. 
 
 Patients with Löfgren´s syndrome had a significantly higher frequency of IL-17-
producing cells in BAL following mKatG stimulation, compared to patients without 
Löfgren´s syndrome. 
 
 HLA-DR3+ sarcoidosis patients with Löfgren´s syndrome had a significantly higher 
concentration of IL-17 in BAL fluid compared to healthy controls and patients 
without Löfgren’s syndrome. 
 
 BAL CD4+ T cells in healthy smokers with normal lung function have significantly 
lower frequencies of IL-17 producing cells compared to healthy never smokers. 
 
 IFNγ/TNF double-producing BAL CD4+ T cells had a significantly higher per cell 
content (MFI value) of both IFNγ and TNF compared to cells that produced either of 
the cytokines alone. This was observed in both sarcoidosis patients and healthy 
individuals. 
 
 IL-10 expression was reduced in BAL CD4+ Foxp3+ T regulatory cells from smokers 
with normal lung function compared to healthy never smokers. 
 
 The fraction of Foxp3+/Helios- Tregs was higher in healthy smokers compared to 
never smokers and IFNγ and IL-10 cytokine production in both smokers and non-
smokers was mainly confined to Foxp3+/Helios- Tregs subset. 
 
 There was a significantly lower ratio of IL-17+ to IL-10+ cells in BAL CD4+ T cells 
in healthy smokers compared to never smokers. 
 
 The cytokine pattern of MS patients indicated a sharp down-regulation of IL-17 
expression by BAL CD4+ T cells in MS patients who received β-interferon or 
natalizumab compared to patients who didn’t received any treatment. 
 
 MS patients who were treated with β-interferon or natalizumab had a tendency toward 
higher percentages of Foxp3+ CD4+ T cells in BAL compared to untreated patients. 
MS non-smokers and MS smokers had significantly fewer IL-10 expressing Foxp3+ 
cells compared to healthy non-smokers. 
 
 The proportion of Foxp3+ BAL CD4+ cells that are Helios+ declined in MS patients, 
while patients who received β-interferon had a tendency towards higher relative 
frequency of Foxp3+ Helios+ cells in the BAL CD4+ T cell compartment. 
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6 CONCLUDING REMARKS AND PERSPECTIVES 
 
The observed heterogeneous responses to mKatG in sarcoidosis patients strengthen the 
hypothesis that mKatG (and other mycobacterial antigens) are pathogenic antigens in a large 
group of patients, and that the quality of the T cell responses against such antigens may 
determine disease outcome. An important question for future studies to address will be to find 
out if there is a way to enhance multifunctional T cell or IL-17 responses, and if so is it 
beneficial at least in a subgroup of sarcoidosis patients? Finding dominant peptide epitopes of 
mKatG in the context of different HLA types is another important task that should shed light 
on the precise pathogenic mechanisms.  In the future, antigen-specific therapy with T cell 
epitopes may be possible for patients with non-resolving disease. 
 
If the lungs are involved in initiation and also propagation of the inflammatory process in 
MS, alterations of BAL Treg phenotype may be of relevance for the pathogenesis. The 
observed effects of treatment on frequency and function of lung Treg cells, and the 
Treg/Th17 ratio in IFNβ-treated patients, may be parts of the mode of action whereby this 
treatment leads to disease amelioration in MS patients. Important questions that remain to 
answer are: what are the functional consequences of the elevated frequency of 
Foxp3+/Helios+ Tregs in IFNβ-treated MS patients? What are the relative roles of different 
Treg subsets in the suppression of auto-reactive T cells? How much similarity is there 
between phenotype and function of the lung and CNS T cells and effect of treatment on Treg 
phenotype in different organs considering that the CNS is the site of auto-aggressive attack? 
What is the role of the lung in the induction versus the regulation of autoimmunity, not only 
in MS but also in other autoimmune disorders such as RA? Further studies of lung T cells in 
MS should help to better understand the immunopathogenesis of this disease, and may 
suggest new approaches to control the inflammatory process. 
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